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Abstract
Hemodialysis (HD) is the most common form of renal replacement therapy for endstage renal disease. However, patients develop complications that are driven by HDinduced circulatory stress from rapidly removing large fluid volumes during HD, making
various vascular beds vulnerable to ischemia. By assessing how HD-induced circulatory
stress affects different organs, it may be possible to characterize the mechanisms behind
these complications and evaluate therapeutic interventions. This thesis aims to explore
how HD affects renal and hepatic blood flow and function using CT perfusion imaging.
For this work, patients received either standard or cooled HD first in a two-visit, crossover
study design, where imaging was performed before, during and after each HD session.
Residual

renal

function

is

linked

to

improved

clinical

outcomes,

yet

characteristically declines upon HD initiation. In the first thesis project, we determined that
renal perfusion decreases during HD, which could be an early manifestation of HDmediated residual renal function loss.
Although the liver normally clears endotoxin, increased circulating endotoxin levels
have been found in HD patients. In the second thesis project, we showed that concurrent
hepatic perfusion redistribution and decreased liver function during HD are likely
responsible for increased circulating toxin levels.
Dialysate cooling is a low-cost, feasible intervention that ameliorates HD-induced
circulatory stress. In the first and second thesis projects, we found that cooling trended
towards mitigating the drop in renal perfusion during HD and ameliorating the changes in
liver perfusion and function during HD.
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If it were possible to accurately assess glomerular filtration rate (GFR) in HD
patients, HD prescriptions could be adjusted in accordance with residual renal function to
preserve remaining function. In the third thesis project, we extended the CT perfusion
technique to measure GFR in HD patients, yielding physiologically realistic GFR values,
thus demonstrating the feasibility of this approach in terms of reliability and accuracy.
These findings help explain residual renal function loss and endotoxemia in HD
patients, and showcases the protective potential of dialysate cooling. In addition, this work
demonstrates the benefit of using CT perfusion as a functional imaging technique to
further characterize and evaluate therapies for end-stage renal disease pathologies.

Keywords: end-stage renal disease, hemodialysis, circulatory stress, computed
tomography perfusion, functional imaging, residual renal function, renal perfusion,
endotoxemia, hepatic perfusion, dialysate cooling, measured glomerular filtration rate
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Lay Summary
Patients with end-stage kidney failure require kidney replacement therapy, with the
most common type being hemodialysis (HD). This treatment removes several litres of
fluid in a 3- to 4-hour session, which stresses the ability of a patient’s heart to pump blood
throughout the body (“circulatory stress”). The goals of this thesis are to explore how
circulatory stress:
•

affects blood flow to, and function of, different organs

•

leads to other health problems besides kidney failure

•

can be prevented to minimize adverse effects on HD patients

These goals were achieved using computed tomography perfusion (CTP), a scanning
technique that measures organ blood flow. We performed CTP on patients before, during
and after HD treatment.
The small remaining kidney function is linked to improved quality of life of HD
patients but declines with HD. In the first thesis project, we found that kidney blood flow
deceases during HD, which could damage the kidney and cause further loss of what little
remaining function there is.
The liver normally clears toxins that it receives from the gut, but HD patients have
abnormally high blood toxin levels. In the second thesis project, we showed that liver
blood flow redistributes to receive more toxin-filled blood from the gut and that the liver’s
detoxification ability was also compromised during HD, leading to increased toxin levels
in HD patients.
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Previous research has shown that by slightly lowering the temperature of the HD
fluid, circulatory stress can be lessened. In the first and second thesis projects, we found
that cooling helped to maintain kidney and liver blood flow during HD.
There is currently no rapid, reliable and accurate method to measure remaining
kidney function in HD patients. In the third thesis project, we extended the CTP technique
to also measure kidney function in our HD patients. This approach yielded realistic values,
thus demonstrating the practicality and utility of our unique method.
These results help explain important health concerns of HD and showcase the
protective potential of cooling. This work demonstrates the benefit of using CTP as a
powerful imaging technique to explore and evaluate therapies for end-stage kidney
failure.
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CHAPTER 1
1
1.1

Introduction
Overview
Chronic kidney disease is a worldwide health burden, with a reported global

prevalence of approximately 13% in 2016.1 In Canada, nearly 4 million people are
estimated to have chronic kidney disease,2 with over 50,000 Canadians living with endstage renal disease and about 58% of those are on dialysis.3 Of those, approximately
75% are receiving hemodialysis,3 which is the most expensive treatment option (costs the
health care system nearly $100,000 per patient per year4), contributes to the development
of other clinical problems (e.g., cardiovascular disease and cognitive impairment), and
results in low survival (5-year survival of 42.8%3).
Although hemodialysis is a life-saving renal replacement therapy which works by
extracorporeally removing accumulated waste products and excess fluid volumes, it is
very socioeconomically draining and physiologically disruptive to the patient. Despite the
multitude of technological and methodological innovations in hemodialysis over several
decades, there has been no improvement in survival for end-stage renal disease patients
receiving this form of renal replacement.5 While this unfortunate reality is in large part due
to the fact that kidney disease patients already carry a high disease burden upon initiation
of hemodialysis, it has become increasingly recognized that hemodialysis therapy itself
plays a major role in the morbidity and mortality of end-stage renal disease patients.6
Therefore, it is extremely important to study the direct physiological effects of
hemodialysis on systemic and multi-organ hemodynamics and function, allowing for the
characterization of clinical complications and development of protective interventions.

1

1.2

The Kidneys

1.2.1 Normal Renal Physiology
The kidneys are important for maintaining homeostasis in the body because they
are responsible for excreting waste products, regulating fluid and electrolyte balance, and
other specialized endocrine functions.7 Normal renal function ensures that fluid does not
accumulate in the body and that unwanted waste products from metabolism do not
buildup in the body. The kidneys receive about 25% of the body’s cardiac output from the
renal arteries, filtering approximately 180 litres of fluid each day in the incoming blood,8
before the filtered blood returns via the renal veins back to the systemic circulation (Figure
1.1A).
Kidneys are composed of an outer layer (cortex) and inner layer (medulla). Each
kidney consists of approximately one million nephrons,8 which are the functional units of
the kidney (Figure 1.1B). Blood enters each nephron through the afferent arteriole,
passes through the glomerulus and its capillaries, and then flows out through the efferent
arteriole. As blood circulates through the glomerular capillaries, excess fluid and
metabolic (potentially toxic) wastes are filtered through the glomerular filtration barrier into
the Bowman’s capsule (Figure 1.1C).9 The glomerulus functions as a macromolecular
sieve: it prevents the filtration of plasma proteins and certain large molecular weight
exogenous tracers while allowing for greater permeability of water and small solutes. The
water-solute filtrate then proceeds into the renal tubule, where tubular secretion and
reabsorption at different points modify the filtrate and prepare it for urinary excretion.9
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Kidney
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Efferent
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Figure 1.1: Basic structure of the kidney, nephron, and renal corpuscle. (A) Kidneys are composed of an
outer layer (cortex) and inner layer (medulla). They receive about 25% of the body’s cardiac output from
the renal arteries, filtering approximately 180 litres of fluid each day in the incoming blood, before the filtered
blood returns via the renal veins back to the systemic circulation. (B) Each kidney consists of approximately
one million nephrons, which are the functional units of the kidney. (C) Blood enters each nephron through
the afferent arteriole, passes through the glomerulus and its capillaries, and then flows out through the
efferent arteriole. As blood circulates through the glomerular capillaries, excess fluid and metabolic wastes
are filtered through the glomerular filtration barrier into the Bowman’s capsule.

The glomerular filtration barrier is composed of 3 layers: endothelium, glomerular
basement membrane, and podocytes.9 The glomerular endothelium consists of flattened,
highly fenestrated cells which are very permeable to water and small solutes, while at the
same time demonstrate charge-selective properties due to negatively charge
proteoglycans in the fenestrae.10 The glomerular basement membrane is a thick, fibrous
network that helps maintain structural integrity and is involved in barrier charge selectivity,
where it accounts for most of the restriction of fluid and solute flux. 10 Podocytes are
specialized epithelial cells lining the outside of glomerular capillaries that have extending
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foot processes separated by filtration slit diaphragms. Podocytes help maintain
glomerular permselectivity by restricting the permeation of macromolecules based on
size, shape and charge.10
The kidney normally has several mechanisms to compensate for fluctuations in
hydration and blood pressure, including the myogenic reflex (pressure receptor-mediated
dilatation of afferent arteriole in response to ischemia), tubuloglomerular feedback (ATPbased afferent arteriole constriction/dilation due to increased/decreased solute delivery
to tubular macula densa cells), and the renin-angiotensin system (ischemia-induced renin
release which constricts the efferent arteriole).11 Under normal physiological conditions,
these mechanisms protect the kidney from ischemic challenges and allow for the
autoregulation of glomerular perfusion, ultrafiltration (UF) pressure, and filtration rate.11

1.2.2 Glomerular Filtration Rate
The primary measure of renal function is the glomerular filtration rate (GFR), which
represents the rate of fluid filtered from the glomerulus into the Bowman’s capsule and is
expressed in mL/min/1.73m2. Glomerular filtration is driven by the hydrostatic and osmotic
pressure gradients between the glomerular capillaries and the Bowman’s capsule:
ℎ𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐

ℎ𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐

𝐺𝐹𝑅 ∝ [(𝑃𝑔𝑙𝑜𝑚𝑒𝑟𝑢𝑙𝑢𝑠 − 𝑃𝐵𝑜𝑤𝐶𝑎𝑝

𝑜𝑠𝑚𝑜𝑡𝑖𝑐
𝑜𝑠𝑚𝑜𝑡𝑖𝑐
) + (𝑃𝐵𝑜𝑤𝐶𝑎𝑝
− 𝑃𝑔𝑙𝑜𝑚𝑒𝑟𝑢𝑙𝑢𝑠
)].9

The

GFR

is

used

clinically to assess the health of the kidneys and as a tool for making informed treatment
decisions.
The GFR can be estimated (eGFR) and measured (mGFR) using various
approaches. eGFR is often assessed using population-based equations which take as
inputs the individual’s demographic information (age, sex, ethnicity) and an endogenous
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marker level reading.12 The most common endogenous markers considered for GFR
assessment are creatinine and urea. Creatinine is a breakdown product of creatine
phosphate from the metabolism of muscle and protein, while urea is waste product of
protein digestion that is produced by the liver. In addition to being filtered, creatinine is
subject to tubular secretion while urea is subject to tubular reabsorption, making both
markers indirect reflections of GFR.12
mGFR can be assessed by taking sequential urine and/or plasma samples of
endogenous or exogenous markers over the course of hours or days. 12 mGFR is most
accurately assessed by performing 24-hour urine collection (since accuracy of plasma
sampling is confounded by extra-renal clearance) following the administration of inulin,
an exogenous marker which does not undergo tubular secretion or reabsorption. Other
common mGFR assessments rely on radionuclide-based urine/plasma sampling of 51CrEDTA (Europe) or 99mTc-DTPA (USA).13
In addition to using inulin and nuclear medicine techniques, GFR can also be
assessed using dynamic CT- and MRI-based approaches by computing the filtration rate
constant (determined from graphical analysis and/or tracer kinetic modelling) and
measuring the kidney mass (determined from volumetric imaging).14-17 In addition to
providing useful anatomical and functional information, imaging-based techniques also
enable the quantification of single-kidney GFR, which has several important clinical
applications (e.g., renal artery stenosis, kidney transplant/donor, comparing left vs. right
kidney function, disease characterization/progression/monitoring/diagnosis, etc.).
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1.2.3 Renal Pathophysiology
1.2.3.1 Acute Kidney Injury
Previously known as acute renal failure, acute kidney injury (AKI) is defined as a
rapid decline in GFR that is represented by either increased serum creatinine levels
(absolute, ≥0.3 mg/dL; percentage, ≥50%; or 1.5-fold from baseline) or reduced urine
production (<0.5 mL/kg/hr for >6 hours), where the injury is reversible.18-20 AKI is grouped
into three main etiologies: prerenal, postrenal, and intrinsic. Prerenal AKI results from a
decrease in renal perfusion which may be caused by hypovolemia, impaired cardiac
output, peripheral vasodilation or renal vasoconstriction, where renal parenchyma is
undamaged following prerenal AKI and injury can be readily corrected with volume
repletion. Postrenal AKI results from obstruction of the urinary tract and urinary flow,
mainly due to cancerous tumors and ureteral stones, and can be treated with surgical
interventions aimed at removing the obstruction. Intrinsic AKI represents the widest
variety of kidney injury and can result from damage to the renal tubules (acute tubular
necrosis due to ischemia or nephrotoxicity which goes though stages of injury, plateau,
and recovery), glomeruli (glomerular damage due to acute glomerulonephritis),
interstitium (acute interstitial nephritis due to infections or drugs/medications), and
vasculature (intrarenal vessel damage due to malignant hypertension, atheroembolic
disease, and vasculitides).21,22
Another important cause of AKI is contrast-induced nephropathy (CIN), which has
traditionally defined by a ≥25% (0.5 mg/dL) increase in serum creatinine levels within 4872 hours of the administration of contrast media.21 Important risk factors for CIN are older
age, diabetes, underlying kidney disease, and hypovolemia, with common prophylaxis
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including using low contrast doses, using iso- and low-osmolarity contrast media,
employing pre-hydration, and temporary halting the administration of compensatory
mechanism-attenuating drugs.21 More recently, the American College of Radiology and
the National Kidney Foundation have separated kidney injury following contrast agent
administration into contrast-associated AKI (any AKI occurring within 48 hours after the
administration of contrast media) and contrast-induced AKI (subset of contrastassociated AKI that can be causally linked to contrast media administration) in order to
emphasize that many clinical manifestations of AKI may be coincident with, but causally
unrelated to, intravenous contrast media administration.23 Although AKI resulting from
CIN has historically been a clinical concern (especially in kidney disease patients who
have impaired renal clearance of contrast), recent literature has disputed the
nephrotoxicity of contrast media, with various clinical trials failing to demonstrate contrastinduced kidney injury.23,24

1.2.3.2 Chronic Kidney Disease
A long-term decrease in renal function is known as chronic kidney disease (CKD).
CKD is divided into 5 stages based on GFR and markers/signs of kidney damage, most
commonly being proteinuria (abnormally high levels of protein in urine). In terms of
decreasing GFR, the stages of CKD are categorized as follows:
CKD Stage
GFR (mL/min/1.73m2)

1

2

3

4

5

≥90

60-89

30-59

15-29

<15
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The two primary causes of CKD in developed countries are diabetes (diabetic
nephropathy) and hypertension (hypertensive nephrosclerosis), followed by other
conditions such as glomerulonephritis, polycystic kidney disease and lupus nephritis.25
In diabetic nephropathy, proteinuria reflects glomerular damage and increased
glomerular permeability to macromolecules. Hyperglycemia in these patients may cause
kidney damage via advanced glycation product accumulation, increased growth factor
expression, and inflammatory factor activation.26 Increased production of angiotensin II
due to hyperglycemia causes negative hemodynamic (induction of systemic
vasoconstriction, increased glomerular arteriolar resistance, increased glomerular
capillary pressure) and nonhemodynamic (increased glomerular capillary permeability,
filtration surface area reduction, extracellular matrix protein enhancement, stimulation of
renal proliferation and fibrogenic cytokines) effects.26 In addition, the glomerular filtration
barrier is harmed by increasing proteinuria resulting from the diabetic state, where
decreased size- and charge-selectivity, reduction in slit-pore density, and prominent
ultrastructural abnormalities lead to decreased filtration barrier effectiveness. In
particular, decreased expression of nephrin and podocin, along with increased endothelin
production (induced by hyperglycemia and angiotensin II), result in podocyte injury,
decreased podocyte density, and increased foot process width, all of which contribute to
loss of glomerular filtration barrier permselectivity.26
In hypertensive nephrosclerosis, chronic systemic hypertension is transmitted to
the glomerular arterioles. Following initial barometric compensation by the afferent
arteriole, long-term constriction of the smooth muscle cells leads to hypertrophy and
barotrauma-induced release of inflammatory cytokines and extracellular matrix
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components (e.g., fibrin and collagen). Hyaline arteriosclerotic lesions form around
endothelial cells, resulting in narrowing of the arteriolar lumen and chronic ischemia which
causes glomerular atrophy and hyalinization.27 In addition to the degree of systemic
hypertension, as well as the transmission of systemic hypertension to the glomerulus, the
development of hypertensive nephrosclerosis also depends on the tissue’s susceptibility
to barotrauma, which is based on genetic factors, proinflammatory conditions, and the
presence of comorbidities (e.g., overactivity of renin-angiotensin system in diabetic
state).28
Complications associated with CKD include cardiovascular disease, anemia,
mineral metabolism abnormalities, and malnutrition.29 Patients with CKD have significant
morbidity and mortality from cardiovascular disease, sharing similar predictors of more
rapid progression (diabetes, hypertension, inflammation, anemia, hypervolemia), as well
as strategies for risk factor reduction. Anemia in CKD is associated with ischemic heart
disease, left ventricular hypertrophy, and impaired quality of life, and maintenance of
erythropoiesis (via iron supplementation or erythropoietin stimulating agents) can
effectively restore hemoglobin levels. Abnormalities in the mineral metabolism of CKD
patients result in altered serum levels of calcium, phosphorous, parathyroid hormone, and
vitamin D, and treatment with supplementation and dietary restriction are needed to
manage hyperparathyroidism and CKD mineral-bone disorder. Malnutrition is common in
late-stage CKD, and extensive guidelines for assessment of nutritional status and dietary
management help mitigate the complications of kidney disease.29
In patients with CKD secondary to diabetic, glomerular, and hypertensive or
vascular diseases, the strongest predictors of more rapid progression are hypertension
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and the degree of proteinuria. Treatment of these conditions in order to control CKD
progression involves lifestyle modification and drug administration (e.g., angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, etc.).29

1.2.3.3 End-Stage Renal Disease
Patients who progress to stage 5 of CKD (i.e., GFR drops to <15 mL/min/1.73m2)
are categorized as having renal failure, or end-stage renal disease (ESRD). In developed
countries, ESRD is most commonly caused by diabetic nephropathy and hypertensive
nephrosclerosis (followed by glomerulonephritis), and patients with ESRD develop a
number of clinical and biochemical disorders related to uremia (abnormally high levels of
nitrogenous waste compounds, such as urea, in blood).3,7 Accumulation of low- and
middle-molecular weight toxins leads to a host of deleterious effects such as
neurotoxicity, reduced drug protein binding, and impaired monocyte function. Loss of
regulation of fluid and electrolytes necessitates dietary modification for limiting sodium,
potassium and water intake. Loss of hormonal functions results in defective production of
erythrocytes and calcitriol, as well as enhanced activity of the renin-angiotensin system.7
As survival at this stage of kidney diseases is extremely poor and preservation of
homeostasis is no longer possible, patients and their healthcare providers must consider
implementing some form of renal replacement therapy. The decision to initiate renal
replacement therapy is usually driven by some combination of extremely low GFR (<10
mL/min/1.73m2), high levels of urea (blood urea nitrogen >120 mg/dL) or creatinine (>10
mg/dL), and severe clinical manifestations (e.g., refractory hypertension, fluid overload,
pericarditis, etc.).7 Once the decision to initiate renal replacement therapy is made, it is
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very important that the patient is prepared both physically (e.g., vascular access for
dialysis) and mentally (e.g., potentially indefinite treatment).7

1.3

Renal Replacement Therapy

1.3.1 Kidney Transplantation
Transplantation is associated with the best survival for all patients, making it the
preferred method of renal replacement therapy (RRT). It requires the patient to undergo
thorough clinical workup to help ensure that the transplant surgery is successful.30
Transplantation can be done with, and is limited by the number/availability of, kidney(s)
from a cadaver (i.e., deceased donor) or living donor. The 1-year kidney graft survival for
living and deceased donor transplantation are 95% and 90%, respectively.30
Although kidney transplant recipients have improved survival compared to patients
receiving other forms RRT, they are still considered to have CKD (irrespective of GFR or
presence/absence of kidney damage markers) and frequently have CKD-related
complications, the prevalence of which increases with declining GFR. The manifestation
of CKD-related complications in a transplant recipient depends on the duration and
degree of kidney disease prior to transplantation, as well as the degree of kidney function
achieved following transplantation (average of approximately 50 mL/min/1.73m2).31

1.3.2 Peritoneal Dialysis
Peritoneal dialysis (PD) is an alternative RRT modality for ESRD patients that has
a number of putative benefits, such as being able to be performed at home due to minimal
mechanical requirements.30 During PD, dialysate is introduced into the cavity of the
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patient’s own peritoneum, which is lined with a capillary-rich membrane. Solutes and fluid
are exchanged between dialysate and blood across the porous walls of peritoneal
capillaries, which act collectively as a dialysis membrane.30
At the initiation of a PD treatment, dialysate fluid, which contains solutes (e.g.,
sodium chloride, bicarbonate) and an osmotic agent (e.g., glucose), is infused into the
peritoneal space. The resulting high osmotic pressure gradient across the peritoneal
barrier (i.e., between dialysate and blood) results in UF, transporting excess water from
blood to dialysate for removal.32 Water is also transported from dialysate to blood due to
the hydrostatic pressure gradient between dialysate (higher pressure) and the peritoneal
tissue interstitium (lower pressure). In addition, bidirectional solute transport through the
peritoneal barrier occurs during PD primarily via concentration gradient-based diffusion.33
Following several hours of treatment, the peritoneal cavity is drained, the dialysate
effluent is discarded, and fresh dialysate is introduced to initiate the next PD cycle.
As long as a patient does not have any abdominal wall defects, they can have a
catheter placed and be put on PD.30 However, most patients cannot remain on PD
indefinitely, and eventually must be switched to hemodialysis (HD). Transferring from PD
to HD may be due to modality-related (e.g., infections, inadequate dialysis, UF failure,
catheter problems), system-related (e.g., lack of infrastructure, lack of patient modality
education/training), and patient-related causes (e.g., patient burnout, loss of residual
renal function, malnutrition, diabetic/abdominal/respiratory complications).34
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1.3.3 Hemodialysis
The most common form of RRT is hemodialysis (HD), which can be done at home
(conventional, short daily, or nocturnal) or, more commonly, in-center, for 4-hour sessions
thrice weekly.30 A patient who is to initiate HD requires some form of vascular access for
repeated access to their circulation, the most preferable form being the arteriovenous
fistula (surgical anastomosis between an artery and nearby vein which matures to allow
for frequent needle cannulation). Other vascular access options include arteriovenous
grafts (interposed synthetic- or bio-graft which connects an artery and vein) and central
venous catheters.35
The goal of HD is to remove excess fluid and accumulated metabolic waste
products, as well as to correct blood electrolyte composition, by the facilitated exchange
between the patient’s blood and a dialysate fluid across a semipermeable membrane.
This process is accomplished via diffusion (transport of solutes between blood and
dialysate based on concentration gradients) and UF (transport of solvent and solutes
between blood and dialysate based on pressure gradients). 7 Therefore, during HD, the
removal of waste products and excess fluid is accomplished via diffusion and UF,
respectively. While UF effectiveness can be assessed with pre- and post-HD patient
weighing (i.e., amount of intradialytic fluid removed), solute removal can be quantified by
the normalized clearance per dialysis, or Kt/V (K = dialyzer urea clearance, t = dialysis
duration, V = urea distribution volume). The Kt/V value, which can be computed from
𝐶 = 𝐶0 ∙ exp[−𝐾𝑡⁄𝑉 ] → 𝐾𝑡⁄𝑉 = ln[𝐶0 ⁄𝐶 ] (where C0 and C are the pre- and post-dialysis
blood urea concentrations, respectively), is a marker of dialysis adequacy which has been
shown to strongly correlate with clinical outcomes.36
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A typical HD circuit (pictured in Figure 1.2) is made up of two sub-circuits: the blood
circuit (patient side) and the dialysate circuit (dialysis machine side).7 The blood circuit
consists of a blood pump (controls blood flow rate), blood pressure sensors, and a
detector which monitors the presence of air within the blood line. The dialysate circuit
consists of a conductivity meter (monitors dialysate composition), temperature and
pressure sensors, flow rate controls, a blood leak detector, dialysate and UF pumps, and
a dialysate flow equalizer (maintains equal inflow and outflow rates). Following each HD
session, the system is disinfected by administering chemical agents into the hydraulic
circuits of the machine.7
Blood
Pressure
Monitor

Ultrafiltration
Pump

Blood Pump

BP

UF
B

Dialysate
Pressure
Monitor
Blood
Leak
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Arterial
Blood
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Figure 1.2: Typical HD circuit, which is made up of two sub-circuits: the blood circuit (patient side, red parts)
and the dialysate circuit (dialysis machine side, black parts). Adapted from Long-term Hemodialysis by
Man, Zingraff and Jungers, 1995.7

14

Dialysate and blood both enter and exit a dialyzer, which contains a porous,
semipermeable membrane across which solutes and solvent are exchanged during HD.
The hollow-fiber dialyzer is the most commonly used type in the clinic, consisting of
several thousand bundled hollow fibers (diameter of 200-300 μm, wall thickness of 10-40
μm). Blood flows within the fibers while dialysate flows between and around the fibers,
allowing for a high area of contact (and therefore a highly efficient exchange) between
blood and dialysate.7,36 The dialysate is composed of various electrolytes (e.g., sodium,
potassium, calcium, magnesium, chloride, acetate, bicarbonate, glucose) and is designed
to correct solute abnormalities which develop in ESRD patients during the interdialytic
interval.7 The two commercially available types of HD membranes are cellulose-based
(chemically treated to improve bioincompatibility) and synthetic (polymer-based,
biocompatible, increasable pore sizes for improved fluid and solute removal).7,36

1.4

Effects of HD on ESRD Patients

1.4.1 HD-Induced Circulatory Stress
Although HD is a life-saving therapy, patients are known to develop a wide range
of complications. An important driving force behind the development of these
complications is thought to be recurrent HD-induced circulatory stress,6 which comes
about as follows: during the interdialytic period, patients accumulate excess fluid and
become hypervolemic. Then during a typical HD session, correspondingly ambitious UF
targets (e.g., high UF volume and rate to achieve a desired post-HD dry weight) result in
a large reduction in plasma volume,6,37 where the rate of fluid removal exceeds the
plasma-refilling rate (i.e., from extravascular to intravascular compartments), leading to
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hypovolemia.7,38 A corresponding reduction in cardiac output,39,40 coupled with autonomic
dysfunction and impaired compensatory physiological responses (e.g., no central
redistribution of blood volume, no increase peripheral vascular resistance),41 leads to
intradialytic hypotension (IDH),7,38 which makes vital organs susceptible to ischemic
challenge and represents the hallmark of systemic HD-induced circulatory stress.6
Approximately one quarter of HD treatments are complicated by IDH (commonly
defined as a symptomatic drop in systolic blood pressure >20 mmHg),7,38 which is an
independent predictor of mortality in HD patients.42 In addition, higher rates of UF (e.g.,
due to higher UF volume requirements and/or shorter HD treatment times) have been
shown to be independently associated with an increased HD patient risk of mortality.37

1.4.2 Effects of HD-Induced Circulatory Stress on Different Organs
Patients with ESRD who are on maintenance HD develop a wide range of clinical
pathologies, and a great deal of research has been dedicated to characterizing the role
HD-induced circulatory stress in the development of these complications. In particular,
various functional imaging techniques have been used to study the hemodynamic
response of multiple vascular beds to HD-induced circulatory stress. This section will
focus on the effects of maintenance HD on the heart and brain.

1.4.2.1 The Heart
Cardiovascular disease is the leading cause of mortality in HD patients. Many
patients have some form of cardiovascular disease at the initiation of HD (e.g.,
atherosclerotic heart disease, heart failure, peripheral vascular disease, previous strokes)
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and are at increased risk of death due to arrythmias and sudden cardiac arrest. 43 To
explore this pathophysiology, myocardial contractile function and perfusion have been
assessed in multiple functional imaging studies.
The hallmark of HD-induced circulatory stress in the heart is myocardial stunning,
which is the delayed recovery of regional myocardial contractile function after ischemiareperfusion despite the absence of irreversible damage and despite restoration of normal
blood

flow.44

Myocardial

stunning

can

be

quantified

using

speckle-tracking

echocardiography, a 2D ultrasound technique which uses specialized software to track
naturally occurring myocardial speckle signals over multiple temporal frames in the
various segments of the left ventricle.45 Next, the magnitude of myocardial deformation in
different directions is resolved, and strain and strain rate curves are generated, from
which the longitudinal strain is measured from the apical long-axis image data.
Longitudinal strain can be assessed globally and segmentally (12 left ventricular
segments), allowing for the determination of the presence of myocardial stunning (defined
as a reduction in longitudinal strain of 20% in two or more segments of the left ventricle
caused by regional wall motion abnormalities (RWMAs)).46,47 Increased development of
RWMAs has been shown to be associated with greater IDH and UF aggressiveness.48 In
addition, HD patients who develop RWMAs over the course of their maintenance HD
therapy have significantly increased mortality and decreased left ventricular ejection
fraction compared to those patients who do not develop RWMAs.48
To identify the association between myocardial stunning and perfusion, dynamic
positron emission tomography (with radiolabeled water, H2150-PET, and nitrogen-13
ammonia,

13N-NH -PET)
3

has been used to demonstrate that myocardial blood flow
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significantly declines during HD.46,49 Contemporaneous echocardiography was used to
identify a relationship between development of RWMAs and a greater reduction in
myocardial perfusion,46 helping to more fully describe the ischemic nature of myocardial
stunning. As a result, the pathological development of cardiovascular mortality in HD
patients could now be summarized as follows: myocardial ischemia-reperfusion injury due
to HD-induced circulatory stress results in myocardial stunning. Over time, recurrent
episodes of myocardial ischemia and stunning result in RWMAs which persist post-HD.
The myocardium is permanently damaged and suffers from contractile dysfunctional,
which eventually leads to arrythmias and sudden cardiac arrest in this patient group.6,44
This process is depicted in Figure 1.3.

Hemodialysis-Induced Circulatory Stress

Myocardial Ischemia (measured with dynamic positron emission tomography)

Myocardial Stunning (measured with echocardiography)

Development and Persistence of Regional Wall Motion Abnormalities

Permanent Myocardial Damage Leading to Chronic Contractile Dysfunction

Arrhythmias and Sudden Cardiac Arrest
Figure 1.3: Pathophysiological progression to cardiac mortality in HD patients. Myocardial ischemiareperfusion injury (measured with dynamic PET) due to HD-induced circulatory stress results in myocardial
stunning (measured with echocardiography). Over time, recurrent episodes of myocardial ischemia and
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stunning result in RWMAs which persist post-HD. The myocardium is permanently damaged and suffers
from contractile dysfunctional, which eventually leads to arrythmias and sudden cardiac arrest in this patient
group.

1.4.2.2 The Brain
Cognitive impairment is common in HD patients, who have been shown to suffer
from important clinical complications such as dementia and depression. 50 Although
cognitive decline develops as kidney disease progresses, the initiation of HD leads to
even greater levels of cognitive impairment and loss of functional status, which have been
linked to higher mortality rates in this population.51 Research studies targeting this
pathophysiology have assessed cerebral hemodynamics, structure and function using
various imaging techniques.
Cerebral

perfusion

has

been

measured

with

dynamic

H2150-PET-CT,

demonstrating a significant decline over the course of HD. 52 Surrogate measures of
perfusion, including cerebral arterial mean flow velocity (with transcranial Doppler
ultrasound) and cerebral oxygen saturation (with near-infrared spectroscopy), similarly
revealed that the brain experiences ischemic challenges during HD. 53,54 In addition to
hemodynamics, structural analysis with T1- and T2-weighted magnetic resonance
imaging (MRI) has revealed three important cerebral pathologies in maintenance dialysis
patients: silent cerebral infarction (asymptomatic ischemic insult which is a predictor for
the development of symptomatic infarcts or hemorrhagic stroke),55,56 cerebral atrophy
(e.g., ventricular enlargement, brain volume reduction, focal lesions), 57,58 and
leukoaraiosis (white matter changes due to ischemia-induced loss of myelin and axons,
and is a risk for dementia and stroke development).59,60 The presence of these
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pathologies represents accelerated vascular aging, is a predictor for the development of
strokes and dementia, and is associated with inflammation, hypertension and vascular
disease.6
In order to spatially correlate cerebral structural abnormalities with functional
measures, diffusion tensor imaging (specialized diffusion-weighted MRI technique),
which can detect ultrastructural white matter abnormalities and assess white matter
structural integrity, has been used for brain imaging in HD patients. 61 This imaging
modality quantifies the diffusion of water molecules within tissue using anisotropy
(assessment of diffusion directionality that represents the integrity of white matter tracts)
and diffusivity (degree of random water motion that represents white matter structural
damage) metrics.62 Research studies utilizing diffusion tensor imaging have collectively
demonstrated two main findings: First, HD patients have significantly different anisotropy
and diffusivity values compared to healthy controls, indicative of white matter damage
and structural integrity loss. Second, after imaging the same HD patient group over two
timepoints separated by 12 months, the observed pattern of quantitative changes (i.e.,
increased anisotropy and decreased diffusivity) matches what is observed in acute
ischemic stroke models and suggests that HD results in significant brain injury.61-63

1.4.3 Strategies to Ameliorate Circulatory Stress
As the role of HD-induced circulatory stress in the development and progression
of complications in ESRD patients has become well-recognized, research studies have
explored various intra- and inter-dialytic strategies that could help mitigate the negative
effects of HD.
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Aggressive UF is one of the primary driving forces of HD-induced circulatory
stress, and stems from the clinical need to remove a certain amount of fluid and/or
metabolic waste products during HD in order to bring the patient’s body weight and
plasma composition to clinically prescribed levels. Conventionally, this is achieved with
thrice weekly HD at 3-5 hours per session. To lessen the strain of UF (and improve both
the control of body fluid volume and clearance of middle molecules), HD treatment times
could be extended, or the weekly frequency of treatments could be increased, both of
which allow for lower UF rates and more sufficient time for removal of larger molecules.6466

In addition to schedule modifications, increased clearance of middle molecules (through

the use of high flux, synthetic dialysis membranes) can help to ease intradialytic UF
burden.64,67 Also, biofeedback HD systems, which monitor intradialytic decreases in
relative blood volume and dynamically lower the UF rate accordingly in order to try and
avoid IDH, have been used to improve the hemodynamic tolerability of HD. 68-70 By
considering these aforementioned issues, it can be understood why PD exerts less
circulatory stress compared to HD: treatment times are generally longer with PD,
intradialytic shifts in fluid volume are more gradual with PD, biocompatibility is inherently
greater with PD, and myocardial stunning is much less frequent with PD.71,72
Numerous research studies have explored hemodynamic protection from HDinduced circulatory stress by applying some form of ischemic preconditioning, which
involves the application of small, controlled ischemic insults prior to a larger, significant
insult in order to improve the circulation’s hemodynamic tolerability and reduce the
magnitude of ischemia-reperfusion injury.73 Ischemic preconditioning can also be applied
remotely (usually by using a blood pressure cuff, inflated to ~200 mmHg, on a peripheral
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limb to induce several cycles of transient ischemia-reperfusion), which works to confer
hemodynamic protection via systemic neuronal and humoral signal transfer. 74 Because
of the consistent, recurrent and predictable nature of HD-induced circulatory stress, HD
represents a favorable model to study ischemic preconditioning, where HD patients stand
to potentially benefit greatly from preconditioning interventions. 75 So far, while only a
handful of studies have explored ischemic preconditioning in HD patients, findings have
been positive (e.g., reduction in HD-induced RWMA development), demonstrating the
protective potential of this technique.76
Another strategy to ameliorate the effects of HD-induced circulatory stress is
dialysate cooling (DC), which involves lowering the temperature of the dialysate (and
therefore the blood via heat exchange) during HD (typically to 35-36°C).77,78 This is a
favorable intervention to apply in HD patients because (1) it does not adversely affect
dialysis adequacy or efficiency, (2) it is universally available and can be implemented at
little-to-no additional cost, and (3) patients are generally tolerable of the lower
temperatures.47 Cooling helps improve systemic vascular resistance, promote peripheral
vasoconstriction, and increase baroreflex sensitivity variability, allowing for increased
shunting of peripheral blood flow to central organs and vascular beds (which are normally
at increased risk of HD-induced ischemic insults), as well as an improved vasoactive
response for the mitigation of IDH. In addition, higher dialysate temperatures have been
linked to increased hemodynamic instability and higher production of nitric oxide, a
vasodilatory agent.79,80 Lastly, cooling lessens organ injury by reducing inflammation,
attenuating oxidative stress, and decreasing free radical production, and has
demonstrated protective potential in multiple organs in the context of therapeutic
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hypothermia.81,82 Multiple studies have explored the effectiveness of DC at ameliorating
the effects of HD-induced circulatory stress, demonstrating that this intervention (1)
lowers IDH incidence,79 (2) abrogates myocardial stunning,47 and (3) maintains cerebral
integrity.62 Some patients report being uncomfortable or having cold-related symptoms
(e.g., shivering) with DC, but alternate cooling approaches such as individualized cooling
(lowering dialysate temperature to 0.5°C below patient’s core temperature) have shown
to mitigate these negative side effects compared to standard fixed-temperature
cooling.62,83,84

1.5

The Liver
The liver receives approximately 25% of the cardiac output. 85 In addition, various

toxins and products of intestinal absorption are prevented from reaching and entering the
systemic circulation by the liver, which receives these substances via the portal circulation
(majority of liver blood flow) and processes them, thereby functioning as a barrier.86
Therefore, the liver may represent another vascular bed that is vulnerable to HD-induced
circulatory stress, a hypothesis which to date has been scarcely explored. In addition to
its effects on hemodynamics, the effects of HD on hepatic function (e.g., liver excretory
function assessment, liver injury assessment) is currently unclear and valuable to study.
The liver is the largest visceral organ, carrying out many important functions.
Hepatocytes (parenchymal liver cells) are involved in uptake, transport, storage,
synthesis, biotransformation and degradation of a variety of substances, including
proteins, lipids, carbohydrates, hormones, drugs and bile. 87 Blood is supplied to
hepatocytes through a specialized capillary system of fenestrated sinusoids, which
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contain Kupffer cells. These macrophagic sinusoidal cells are responsible for
maintenance of normal liver function, and are involved in processes such as phagocytosis
of particulate matter, detoxification and clearance of endotoxin, secretion of mediators,
etc.87
The liver’s total blood supply is divided into two components: approximately 30%
comes from the high-pressure, well-oxygenated hepatic artery (branches from abdominal
aorta), while the remaining 70% comes from the low-pressure, mildly-oxygenated,
nutrient-rich portal vein (outflow from splanchnic organs).85 These blood supplies meet,
mix and travel through the network of sinusoids, allowing for exchange of oxygen,
substrates and metabolites with hepatocytes.87 Due to its unique dual blood supply, the
liver can effectively regulate its blood flow via the hepatic arterial buffer response, which
works to increase/decrease hepatic arterial perfusion in response to a decrease/increase
in portal venous perfusion.85

1.6

Other Important Issues in HD Patients

1.6.1 Loss of Residual Renal Function
Most ESRD patients who start on RRT are not completely anuric and still produce
some small volumes of urine on a daily basis.88 This small level of remaining GFR, known
as residual renal function (RRF), provides several important physiological advantages
that cannot be substituted with RRT, such as secretion of organic acids, various
endocrine functions, and a more liberal fluid intake for patients. 89 The presence and
preservation of RRF after HD initiation is associated with a host of beneficial effects,
including: better control of serum electrolytes, hypervolemia and hypertension, improved
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nutrition, reduced blood pressure, left ventricular atrophy and anemia, and higher middle
molecule clearance.90,91 This latter effect is especially valuable, as middle molecules
(uremic toxins weighing 500-60000 Daltons) represent relatively large solutes that are
readily cleared by the native kidneys but are difficult to remove with conventional HD (i.e.,
require high-flux membranes and/or increased treatment time).36
Preserved RRF is strongly associated with improved HD patient survival.92 Even
minimal amounts of RRF have been shown to be associated with improved survival,
where every additional 0.5 mL/min/1.73m2 increase in residual GFR is associated with a
7% increase in survival and a 250 mL increment in urine output correlates with a 36%
decrease in the relative risk of death.93 The importance of long-term RRF maintenance
has been emphasized by the 2006 National Kidney Foundation KDOQI Guidelines, which
recommended that “one should strive to preserve RKF in HD patients”.94
Despite its importance in conferring health and survival benefits, RRF
characteristically declines rapidly in patients with ESRD upon initiation of RRT, with a
faster rate of decline for HD compared to PD (although both decline by approximately
50% or more during the first 12 months of RRT).89 This decline has consistently been
linked to poorer outcomes and increased mortality.95 As RRF declines, more aggressive
fluid removal in subsequent HD sessions becomes necessary, increasing the burden of
HD-induced circulatory stress.
Numerous factors are associated with RRF decline, such as age, CKD cause,
bioincompatible dialysis membranes, hypertension, and hemodynamic instability during
HD (e.g., IDH).96 While the pathophysiological mechanism(s) behind RRF loss in HD
patients remain unknown, it has been hypothesized that recurrent ischemic insults to the
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kidney parenchyma (i.e., renal manifestation of HD-induced circulatory stress) may cause
permanent, irreversible injury leading to declining RRF.97,98 However, research studies to
date have not focused on measuring intradialytic renal perfusion and confirming the
presence of HD-induced renal ischemia. In addition, the relationship between renal
perfusion with RRF loss has not been explored, preventing the evaluation of potential
preservation interventions.

1.6.2 Endotoxemia
Endotoxin is a gut-derived proinflammatory agent. It is found on the cell wall of
gram-negative bacteria in the gastrointestinal tract and consists primarily of
lipopolysaccharide.99 Endotoxin is a natural constituent of portal venous blood and is
therefore normally received by the liver from the gut.100,101 Under healthy conditions,
hepatic Kupffer cells efficiently and selectively phagocytose and clear endotoxin,102
limiting its presence in the systemic circulation.
However, increased endotoxin levels (i.e., endotoxemia) have been found in HD
patients, with higher amounts of endotoxin compared to both the general population and
to earlier stage CKD patients.103 Endotoxemia in HD patients has been shown to be
associated with drivers of HD-induced circulatory stress (UF and IDH), markers of injury
and inflammation (cardiac troponin T and C-reactive protein), cardiovascular
complications (myocardial stunning and left ventricular dysfunction), and a higher risk of
mortality.103,104 Upon entering the system circulation, endotoxin complexes with CD14
and lipopolysaccharide binding protein,105 which goes on to activate monocytes and
macrophages, as well as to increase the levels of proinflammatory cytokines (e.g., TNF-
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α, IL-6).106,107 This results in a systemic chronic inflammatory state, which is characteristic
of ESRD patients on HD and known to be correlated with an increased risk of
cardiovascular disease.103
Increase endotoxin translocation across the intestinal barrier during HD is
understood to come about as follows: ESRD patients characteristically show signs of gut
mucosal ischemia (such as gastric intramucosal acidosis),108 which, when compounded
with intradialytic hemodynamic effects (such as HD-induced circulatory stress leading to
reduced splanchnic blood volume),109,110 results in mesenteric ischemia.103 This
hypoperfusion has previously been shown to alter bowel morphology, permeability, and
hemodynamics, resulting in the disruption of gut mucosal structure and function, and an
increase in gut permeability.111 Consequently, there is a loss in the selective barrier
function of the bowel,111 leading to increased translocation of enteric bacterial products
(such as endotoxin) across the intestinal barrier.112
Understanding that the liver normally functions as an endotoxin barrier, that there
is increased translocation of endotoxin during HD, and that HD patients are
characteristically burdened by endotoxemia, it is reasonable to suggest that HD may
somehow disrupt liver hemodynamics and function. By studying the liver’s response to
HD-induced circulatory stress (which may be quite different from other organs due to its
unique dual blood supply), it may be possible to better understand how HD leads to the
perpetuation of endotoxemia. In addition, understanding the liver’s role in endotoxemia
may offer the opportunity to develop effective mitigation strategies.
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1.6.3 No GFR Measurement Method That Is Accurate and Feasible
As discussed in section 1.6.1, maintenance of RRF is extremely valuable in terms
of yielding improved clinical outcomes and quality of life. However, despite its importance,
a patient’s RRF is rarely taken into account during the design of their dialysis prescription,
and instead, incident HD patients are most commonly prescribed the clinical standard of
thrice-weekly HD.113-115 Various studies have demonstrated that compared to patients
initiating RRT with incremental HD (i.e., starting with once- or twice-weekly HD, and
increasing frequency of weekly HD sessions in accordance with decreasing RRF), those
initiating with thrice-weekly HD tended to lose RRF faster in the first 12 months of HD and
have a lower survival.95,114,115 Therefore, adjusting a patients’ HD prescriptions based on
changes in their RRF may yield better outcomes for ESRD patients, and the importance
of this philosophy has been emphasized by the 2015 KDOQI Hemodialysis Adequacy
Guidelines, which state that “…in patients with significant residual native kidney function
(Kru), the dose of hemodialysis may be reduced provided Kru is measured periodically to
avoid inadequate dialysis”.116
In order to fully realize this treatment philosophy, the assessment of renal function
(i.e., GFR) must be accurate, reliable and feasible. Estimation of GFR (i.e., eGFR) from
population-based equations is unsuitable for HD patients, as these equations are based
on data collected from earlier stage CKD patients and generate erroneous results when
applied to the ESRD population.12,114 Therefore, measurement of GFR (i.e., mGFR) is
necessary in this patient group, which is conventionally achieved via urinary or plasma
clearance of endogenous or exogenous filtration markers. However, a number of
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disadvantages associated with these mGFR techniques limit their use clinically,
particularly in HD patients:8,12,13,114,117-119
•

Endogenous marker (e.g., creatinine, urea, etc.) levels directly affected by HD and
are not in a steady state during the interdialytic period

•

Urine sampling is unreliable (e.g., patient-dependent) and cumbersome (e.g., 24hour collection time, may require urinary catheterization, etc.)

•

Plasma sampling takes a long time (i.e., determination of disappearance curve
takes longer with lower GFR) and is inaccurate due to extrarenal elimination of
filtration marker (even greater effect at lower GFR)

•

Issues with availability and/or accessibility of certain exogenous markers (e.g.,
inulin in limited supply, 51Cr-EDTA and

99mTc-DTPA

not commercially available in

the United States and Europe, respectively, etc.)
•

No standardization of assays used to measure filtration marker levels

•

Impossible to assess single-kidney GFR
These limitations may be overcome by measuring GFR using medical imaging

approaches. Compared to standard mGFR methodology, imaging-based mGFR can be
obtained rapidly, does not require urine and/or plasma sampling, and can be assessed
contemporaneously with additional structural and functional information.14 Over the past
several decades, a multitude of research studies have explored the use of nuclear
medicine-, CT-, and MRI-based approaches for measuring GFR in both animal and
human subjects in various clinical contexts (e.g., renal cell carcinoma, chronic kidney
disease, etc.), showing strong agreement with standard mGFR methods.16,17,120-124
However, these techniques have never been applied in the context of ESRD and/or HD
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patients. Therefore, there is currently no go-to clinical GFR quantification approach
available for this population that can provide a rapid, reliable and accurate measurement
of kidney function, which is a key requirement for RRF-based HD prescription adjustment.

1.7

CT Perfusion Imaging of Body Organs
In order to address these three issues in HD patients (i.e., loss of RRF,

endotoxemia, no GFR measurement method for patients that is accurate and reliable), it
is necessary develop methods to measure kidney and liver blood flow and associated
hemodynamic parameters (particularly, for the case of kidneys, the extraction efficiency
of glomerulus filtered agents like CT contrast agents). Assessment of kidney perfusion is
required to confirm that HD-induced circulatory stress causes recurrent kidney ischemia,
assessment of liver perfusion is required to explore whether HD leads to increased
endotoxin influx from the gut, and assessment of extraction efficiency of glomerulus
filtered agents125 is required to test the feasibility of GFR measurement in HD patients.
Computed tomography perfusion (CTP) imaging was used in these developments.

1.7.1 Overview of CTP
CTP is a dynamic radiological imaging technique that measures temporal changes
of the x-ray attenuation characteristics in an object/region of interest (e.g., kidney and
liver) from an exogenous iodinated contrast agent injected into the systemic circulation.126
Compared to static imaging with/without contrast (which provides anatomical/structural
information in a single temporal snapshot), dynamic imaging captures changes occurring
over time via a series of images performed at a single anatomical location following
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contrast agent administration, enabling the study of physiological processes that change
over time.127 Upon contrast injection, CTP allows investigation of two processes in kidney
function (kidney is used as an illustrative example, and the following discussion applies
to other organs/tissues): (1) delivery of contrast (as marker for metabolic waste) by blood
flow to the afferent arterioles, and (2) permeation of the glomerular filtration barrier (the
basis of glomerular filtration rate measurement, see Chapter 4).128 These two processes
would lead to a transient increase (wash-in) and decrease (wash-out) of contrast agent
(concentration) in the kidney over time, which can be measured by a CT scanner as
changes in x-ray attenuation (or density in Hounsfield units or CT number). Note that xray attenuation is a physical process involving energy much higher than the chemical
reaction/interaction of contrast agent with the other molecules within the tissue
microenvironment, making CTP highly linear with contrast concentration, a prerequisite
for physiological (kinetic) modelling.128

1.7.2 Tracer Kinetic Modelling
Tracer kinetic modelling mathematically models the processes involved in the
distribution of blood borne tracer (e.g., CT contrast agent) in the target tissue in as few
parameters as possible. One class of tracer kinetic models is compartment models, which
categorize tracer within tissue into two or three compartments – blood, free and bound
tracer – where within each, tracer is assumed to be uniformly mixed and tracer
concentration is only dependent on time. Except for the blood compartment, the other
compartments may not exist in physically reality, but are nevertheless useful
mathematical constructs to facilitate the description of tracer distribution in tissue over
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time once the tracer is introduced into the systemic circulation. Treating blood vessels as
a compartment assumes that fresh tracer arriving via afferent arterioles will mix
instantaneously and uniformly with tracer already in the glomerulus and, more
importantly, will filter through the glomerular filtration barrier at a constant rate. However,
in real situation, because of the continuous loss of tracer via filtration, there is a tracer
concentration gradient from afferent to efferent arterioles, so the filtration rate is not
constant during the blood (vascular) transit time of the glomerulus.128 When tissue tracer
concentration was measured at time intervals shorter than the vascular transit, Larson et
al. showed that blood flow estimated with compartment models can be erroneous.129
To avoid the compartment assumption for blood vessels (so as to minimize error
in blood flow estimation when the time interval of contrast concentration measurement is
short as in CTP studies), in this thesis we used a distributed parameter model to model
the blood vessels as a tube with a concentration gradient from the arterial to the venous
end.128 This reflects the filtration of solute across the glomerular filtration barrier into the
Bowman’s capsule as blood travels down the length of the glomerular capillaries. The
distributed parameter model used is the Johnson-Wilson model shown schematically in
Figure 1.4.128,130
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x
Interstitial Space
Ce(t), Ve
F∙Ca(t)

Intravascular Space
Cb(x,t), Vb

F∙Cv(t)

PS

Figure 1.4: Schematic of Johnson-Wilson model. Blood vessels are modelled as a tube. There is filtration
of solute (contrast) across the blood-tissue barrier (in the case of kidneys, the glomerular filtration barrier)
into the interstitial space as blood travels down the length of the tube, creating a concentration gradient
from arterial to venous ends. F = blood flow, Ca(t) = arterial contrast concentration (i.e., arterial input
function), Ce(t) = venous contrast concentration, PS = permeability-surface area product, Cb(x,t) =
intravascular contrast concentration, Vb = intravascular volume, Ce(t) = interstitial contrast concentration,
Ve = interstitial volume. Adapted from CT imaging of angiogenesis by Lee, Purdie and Stewart (Q J Nucl
Med, Vol 41, p171-187, 2003).131

1.7.3 Deconvolution
A central concept in tracer kinetic modelling is the flow-scaled impulse residue
function, RF(t), which is the tissue tracer (contrast) concentration in response to a bolus
injection of a contrast mass (numerically) equal to blood flow (F) at the afferent
arterioles.128 If the contrast distribution process(es) in the kidney is unchanging with time,
then by the principle of superposition, in response to a systemic injection of contrast giving
rise to contrast concentration at the afferent arterioles, C’a(t), the tissue contrast
concentration, Q(t), is given by:
𝑄(𝑡) = 𝐶𝑎′ (𝑡) ⊗ 𝑅𝐹 (𝑡)
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where ⊗ is the convolution operator. As is usually the case, the afferent arterioles, or
even afferent artery, is too small to be visualized by CT. As a result, contrast
concentration, Ca(t), could be measured at a large artery such as the renal artery or aorta.
In that case, C’a(t) is assumed to be a time-shifted version of Ca(t), which is expressed
mathematically as:
𝐶𝑎′ (𝑡) = 𝐶𝑎 (𝑡 − 𝑇0 )
Where T0 is the delay in contrast arrival at the afferent arteriole relative to the large artery
where Ca(t) is measured. The flow-scaled impulse residue function, RF(t), of the JohnsonWilson model (as depicted in Figure 1.5) can be expressed as:
𝑅𝐹 (𝑡) = {

𝐹
𝐹 ∙ 𝐸 ∙ 𝑒 −𝑘(𝑡−𝑀𝑇𝑇)

, 0 ≤ 𝑡 ≤ 𝑀𝑇𝑇
, 𝑡 > 𝑀𝑇𝑇

where k (= FE/Ve) is the efflux rate constant. Thus, the distribution of blood borne contrast
in the kidney as described by the Johnson-Wilson model can be summarized by four
parameters – blood flow (F), extraction efficiency of contrast (E), mean transit time (MTT)
and contrast distribution volume (Ve).
In a CTP study, Ca(t) and Q(t) are measured as changes in CT number over time
(i.e., time-density curve, TDC) in a larger artery region and the kidney, respectively, and
are used to calculate RF(t) by a mathematical operation called deconvolution. Whereas
RF(t) is the tissue TDC in response to a Ca(t) that is very brief (delta function) from a bolus
injection at the afferent arteriole, Q(t) corresponds to a more drawn out C a(t) from a
systemic injection. Thus, to get RF(t) from Q(t), the influence of Ca(t) has to be removed
via deconvolution. This is achieved by iteratively changing the four parameters of R F(t) –
F, MTT, E and k – and T0 so that the convolution of RF(t) with Ca(t–T0) will minimize the
sum of squared deviations from the measured Q(t).128 When the measured Ca(t) is
34

systematically deconvolved from Q(t) for each small discrete region (for instance, 3⨯3
pixels) in a CT image, the different parameters obtained can be assembled together to
form a parametric (e.g., blood flow, F) map. This process is illustrated in Figure 1.6 in the
case of computing kidney blood flow.

MTT

F

F∙E

e–k(t–MTT)

Figure 1.5: Johnson-Wilson model blood flow-scaled impulse residue function. F = blood flow, E = extraction
efficiency, MTT = mean transit time, T0 = contrast arrival time, k = F∙E / Ve = efflux rate constant. Adapted
from CT imaging of angiogenesis by Lee, Purdie and Stewart (Q J Nucl Med, Vol 41, p171-187, 2003).131
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Q(t)

Ca(t)

RF(t)

F

e–k(t – MTT)
F∙E

⊗

=

MTT
Figure 1.6: Application of tracer kinetic modelling to the computation of physiologic parameters (e.g., renal
blood flow). From the dynamic series CT images, the baseline subtracted arterial TDC is deconvolved from
each baseline subtracted tissue TDC (i.e., individual tissue curve for each 3⨯3 pixel block in the CT image)
to estimate model (functional) parameters of the flow-scaled impulse residue function (based on non-linear
least squares curve fitting), yielding parametric maps (such as blood flow).

1.7.4 CTP Imaging of Liver Perfusion
As discussed in the previous section, measurements of the arterial and the tissue
time-density curve are required in order to perform deconvolution and extract functional
parameters related to tissue perfusion. While the tissue enhancement (CT density
change) of most organs (including the kidneys) results from the inflow of contrast from
arteries (i.e., Ca(t) measured from aorta), enhancement of liver parenchyma results from
the combined inflow from the hepatic artery and portal vein.132 However, the portal vein
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TDC, CPV(t), cannot be approximated by that of the hepatic artery, CHA(t). There is an
inherent delay between contrast agent delivery through the arterial and portal routes:
while hepatic arterial blood branches off and arrives directly from the abdominal aorta,
portal venous blood is delayed and diluted as it passes through and drains from the
splanchnic organs. Owing to these aspects of the liver’s blood supply, quantification of
hepatic perfusion can be separated into the hepatic arterial and portal venous
components by splitting up the arterial input function into two parts:
𝑄(𝑡) = 𝐶𝑎 (𝑡) ⊗ 𝑅𝐹 (𝑡) = [𝛼 ∙ 𝐶𝐻𝐴 (𝑡) + (1 − 𝛼) ∙ 𝐶𝑃𝑉 (𝑡)] ⊗ 𝑅𝐹 (𝑡)
Here, α is the hepatic perfusion index (also known as the hepatic arterial fraction), which
is the ratio of hepatic artery perfusion to total liver perfusion (i.e., sum of hepatic artery
and portal vein perfusion) and is computed as an additional parameter during
deconvolution.132

1.8

Motivation and Objectives of Thesis
Millions of people around the world are afflicted by CKD. While HD is an effective

treatment for those who progress to ESRD, it inflicts recurrent circulatory stress during
each treatment session, thereby perpetuating a host of comorbidities in this patient
population. The quantitative characterization of these hemodynamic perturbations
(including GFR measurement) may inform the development of effective adjunctive
treatments to potentially slow RRF loss and mitigate endotoxemia.
Because HD is typically administered in a clinical setting, performing hemodynamic
measurements using non-invasive and minimally disruptive methodology, such as
advanced functional imaging, is highly desirable. Being able to assess the effects of HD-

37

induced circulatory stress on multi-organ hemodynamics during live HD sessions can
provide novel insights into how certain complications develop in this patient population,
and how these developments may be slowed or stopped. This thesis will describe the
application of CTP imaging to ESRD patients on HD in order to explore the effects of this
treatment modality on renal and hepatic blood flow and function.
This thesis is divided into three research projects (chapters 2, 3 and 4) with the
following objectives:
•

Project 1: effects of HD on kidney blood flow, and relationship to RRF loss
o Examine how HD affects renal perfusion
o Explore the relationship between changes in renal perfusion and myocardial
dysfunction (a hallmark of HD-induced circulatory stress) during HD
o Investigate whether cooling can protect the kidneys from HD-induced
circulatory stress

•

Project 2: effects of HD liver blood flow and function, and relationship to endotoxemia
o Examine how HD affects hepatic perfusion and function
o Explore the relationship between changes in hepatic perfusion and endotoxin
levels during HD
o See if cooling can maintain liver hemodynamics and limit systemic exposure to
endotoxin

•

Project 3: measuring GFR in HD patients using CTP
o Develop methodology for CTP-based GFR assessment
o Explore the feasibility of using CTP imaging to quantify GFR in HD patients
o Assess how GFR changes over the course of HD
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CHAPTER 2
2

Renal Perfusion during Hemodialysis: Intradialytic Blood Flow Decline and
Effects of Dialysate Cooling
Residual renal function confers survival in patients with end-stage renal disease

but declines after initiating hemodialysis. We used CT perfusion imaging to explore
whether hemodialysis-induced circulatory stress causes renal ischemia, which could help
explain residual renal function loss in this patient population.
The contents of this chapter were adapted from an original research manuscript
entitled “Renal Perfusion during Hemodialysis: Intradialytic Blood Flow Decline and
Effects of Dialysate Cooling”, which was published in the Journal of the American Society
of Nephrology in 2019 and co-authored by Raanan Marants, Elena Qirjazi, Claire Grant,
Ting-Yim Lee and Christopher McIntyre. The permissions to reproduce this manuscript
are provided in Appendix E.

2.1

Introduction
Most patients on incident hemodialysis (HD) are not completely anuric.1,2 The

presence and preservation of even minimal amounts3-6 of residual renal function (RRF)
after HD initiation is associated with better control of serum phosphate, hypervolemia,
and hypertension, improved nutrition, less anemia, higher middle molecule clearance,
and improved survival.7-12 Although the importance of long-term RRF maintenance is
recognized,13 RRF characteristically declines after HD initiation, necessitating more
aggressive fluid removal in subsequent HD sessions.14,15 This decline is linked to poorer
outcomes and increased mortality.12,16
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Observational studies have found that age, chronic kidney disease (CKD) cause,
bioincompatible dialysis membranes, and elevated blood pressure (BP) are associated
with RRF decline.9,17,18 Larger epidemiologic studies have confirmed these findings and
shown that hemodynamic instability during HD (i.e., intradialytic hypotension, IDH) is
independently associated with RRF loss.14,19
Intradialytic circulatory stress is associated with reduced perfusion in multiple
vulnerable organs.20 Recurring subclinical ischemic injury over many HD sessions is
linked to increased morbidity and mortality. One strategy that reduces IDH frequency (an
independent predictor of mortality14) and ameliorates HD-induced circulatory stress is
dialysate cooling (DC).21,22 This intervention does not adversely affect HD efficiency, is
generally well tolerated, and can be widely implemented at no additional cost.23 Studies
have found that myocardial and cerebral perfusion can be preserved using DC, providing
protection against injury and longer-term organ dysfunction.22,24,25
Several authors have speculated that HD causes recurrent renal ischemic insults,
which may cause irreversible injury leading to RRF loss.10,11,26 However, trials to date
have not focused on measuring HD-induced renal ischemia or describing its relationship
with RRF loss, preventing the evaluation of potential preservation interventions. We
therefore conducted a pilot study of whole organ kidney perfusion, measured serially
during HD using computed tomography (CT) perfusion imaging, to measure intradialytic
renal perfusion and test two hypotheses: first, that HD is associated with acute renal
perfusion decline, and second, that DC ameliorates HD-induced changes in renal
hemodynamics. Confirming quantitatively that HD does in fact result in decreased renal
perfusion (DRP) will represent the first crucial step toward the pathophysiologic
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characterization of HD-mediated RRF loss in patients with end-stage renal disease
(ESRD).

2.2

Methods

2.2.1 Patients
Thirty patients (19 men) in total from the London Health Sciences Centre Regional
Renal Program were enrolled in two experiments (see Study Design below), after giving
their written informed consent. Adult patients established on HD for at least 3 months and
who had low RRF (<250 mL/day) were eligible. This group of patients with already low
RRF was selected to limit any potential effects of contrast-induced nephropathy.
Exclusion criteria included active infection/ malignancy, pregnancy, breast feeding,
planned pregnancy, diabetic with hypoglycemia during HD within the past 2 months, and
known allergy to iodinated contrast agent. These experiments were approved by the
University of Western Ontario Health Sciences Research Ethics Board and were
conducted in compliance with the approved protocols, Good Clinical Practice Guidelines,
and all applicable regulatory requirements.

2.2.2 Study Design
Two back-to-back pilot experiments were conducted and then the results were
combined. In the first experiment, 14 patients were recruited to undergo a single session
of standard dialysate temperature (36.5°C) HD. In the second experiment, 16 patients
were recruited to undergo two sessions of HD: one session of standard dialysate
temperature HD and another of cooled dialysate temperature (35.0°C) HD. Patients
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involved in the second experiment were randomly assigned to receive either standard or
cooled HD first in a two-visit crossover study design, thereby acting as their own controls.
Combined findings from the two experiments were divided into “standard HD”
(14+16=30 standard HD patients) and “standard versus cooled HD” (16 standard and
cooled HD patients) and analyzed accordingly. All patients underwent uninterrupted HD
in the CT scanner room. Analysis of the imaging data from the crossover experiment was
performed with the operator blinded to allocation. Patients, dialysis unit staff, and the
investigator at the experiment visit were not blinded to the intervention, but were not
involved in the imaging data analysis.

2.2.3 Dynamic CT Image Acquisition and Analysis
CT perfusion imaging was performed on a GE Healthcare Revolution 256-slice CT
scanner at three times during each HD session: immediately before, 3 hours into (i.e.,
peak stress, defined from previous studies of HD-induced myocardial injury), and 15
minutes after dialysis. For the intradialytic scan, patients were transferred to the CT bed
without interrupting their HD treatment. After iodinated contrast agent injection (at a rate
of 5 mL/s, followed by a 30 mL saline flush), dynamic contrast-enhanced CT scanning of
a 16 cm section of the abdomen was performed without breath hold. The type of contrast
agent, iopamidol (Isovue 370; Bracco Imaging), was identical in all patients for both
standard and cooled HD sessions, and was administered at a dose of 1 mL/kg of pre-HD
patient weight (up to a maximum dose of 70 mL).
Scan ranges were optimized to encompass as much of both kidneys as possible
by performing a non-contrast localization scan prior to each CT perfusion scan. The
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section was divided into 32 slices of 5 mm thickness each, and was scanned 42 times at
2.8 second intervals using 120 kV and 22.4 mAs, for a duration of approximately 2
minutes. Images were reconstructed using 100% Adaptive Statistical Iterative
Reconstruction (GE Healthcare) to reduce image noise, and then registered using
nonrigid registration (GE Healthcare) to minimize breathing motion among images of the
dynamic scan. Registered images were analyzed using CT Perfusion 4D software (GE
Healthcare). An aortic region of interest (ROI) was selected for generation of renal
perfusion (i.e., blood flow) maps (this process is described in section 1.7.3). Next, ROIs
were manually drawn over the kidneys in the blood flow maps to encompass medullar
and cortical areas. Kidney ROIs were reviewed and verified by three experienced (>10
years) radiologists. Then, perfusion values were averaged over the selected slices to
determine mean whole kidney blood flow values.
DRP was defined as either (1) a drop in blood flow at peak stress ≥2 SEM (SEM
of the patient group), or (2) a drop in blood flow at both peak stress ≥1 SEM and after HD
≥1 SEM.

2.2.4 Echocardiography Analysis of Myocardial Stunning
Myocardial response to HD was assessed to provide a reference to another critical
organ known to be vulnerable to HD-induced circulatory stress. Echocardiography was
performed by trained investigators before commencing and 15 minutes before the end of
HD, using commercially available equipment (1.5–3.6 MHz M4S probe, Vivid-iq; GE
Healthcare). Standard apical two- and four-chamber views were recorded for offline digital
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analysis with a semi-automated computer program (EchoPac; GE Healthcare) using twodimensional speckle tracking software.
Images were anonymized and analyzed in random order by the same trained
investigators (E.Q. and C.G.). Three cardiac cycles at each time point were analyzed to
derive segmental (12 left ventricular segments) and global longitudinal strain. Myocardial
stunning (MS) was defined as a reduction in longitudinal strain of >20% in two or more
segments of the left ventricle caused by regional wall motion abnormalities (RWMAs).
The number of left ventricular segments exhibiting a reduction in strain of >20% was also
recorded.

2.2.5 Statistical Analyses
Kidney perfusion has never been assessed previously in the context of HD and
inadequate data exist to perform a meaningful sample size calculation. As the initial proofof-principle study for hypothesis generation, a sample size of approximately 15 patients
per pilot experiment is not powered for analysis of the data with inferential statistics.
However, the proposed sample size has been selected on a pragmatic basis and is
comparable with published norms22,27,28 and recommendations.29,30
Statistical analysis was performed using SPSS, version 25.0 (IBM, Chicago, IL).
Data were analyzed using repeated measures ANOVA with post hoc t tests (with
Bonferroni correction) and patient baseline-adjusted ANCOVA to detect differences
between groups. Associations between variables were assessed using the Pearson
product-moment correlation coefficient, and the McNemar test was used to detect
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differences between proportions. Two-tailed P values <0.05 were considered statistically
significant.

2.3

Results

2.3.1 Clinical Characteristics of Study Population
Thirty patients (19 men) aged 40–84 years were enrolled in two back-to-back
experiments. However, one patient could not return for the second visit of the crossover
experiment and was excluded from the analysis, resulting in 29 standard HD patients, 15
of which also underwent cooled HD. The median dialysis vintage was 5.3 years (range,
0.8–46 years). Ten patients had known coronary artery disease, seven had congestive
heart failure, four had peripheral vascular disease, 15 had diabetes, and 25 had
hypertension. Dialysis session length ranged from 2 to 4 hours (median, 3.5 hours) and
ultrafiltration (UF) ranged from 0 to 41 mL/kg (median 23 mL/kg). Table 2.1 presents the
summary of patient baseline characteristics.
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Table 2.1: Baseline characteristics of first project study population.
Mean (Range)a

Characteristics
n (standard HD, cooled HD)

29 (29,15)

Age

64 (40–84)

Men, n (%)

19 (66)

Dialysis vintage, years

5.3 (0.8–46)

Coronary artery disease, n (%)

10 (34)

Congestive heart failure, n (%)

7 (24)

Peripheral vascular disease, n (%)

4 (14)

Diabetes, n (%)

15 (52)

Hypertension, n (%)

25 (86)

Length of HD session, hours

3.5 (2.0–4.0)

UF, mL/kg
aUnless

23.3 (0.0–40.9)

otherwise specified.

2.3.2 Renal Perfusion
Baseline renal perfusion and renal hemodynamic response to HD differed between
both kidneys to a measurable extent for many patients. Therefore, perfusion data analysis
was on the basis of individual kidneys among all patients.

2.3.2.1 Standard HD
Perfusion was measured in all 29 patients, resulting in computed values for 57
kidneys (one patient had a solitary kidney). Average baseline per kidney perfusion was
33.2±2.9 mL/min/100g (mean±SEM) and correlated with dialysis vintage (r=-0.35;
59

P<0.01). At peak stress, average per kidney perfusion dropped to 81.6%±4.8% of
baseline (Figures 2.1 and 2.2A). After HD, average per kidney perfusion recovered to
95.1%±5.2% of baseline (Figure 2.2A). After repeated measures ANOVA, post hoc
analysis revealed that the intradialytic renal perfusion drop was statistically significant
compared with pre- and post-HD (P<0.005). Acute DRP during HD was observed in 37
out of 57 kidneys (65%), where average per kidney perfusion dropped to 61.4%±3.6% of
baseline during peak stress. For the remaining 20 kidneys (35%), average per kidney
perfusion increased to 119.9%±5.2% of baseline at peak stress (Figure 2.2A).
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0
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D

Figure 2.1: HD-induced decrease in kidney blood flow visualized with parametric renal perfusion maps.
Renal blood flow at baseline (A and C) and 3 hours into dialysis (B and D) for two patients (top and bottom
rows). Kidneys have been identified (white arrows and dotted contours) for both patients.
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–––-Patients without Kidney Stunning
–––-Patients with Kidney Stunning––––
–––-All Standard HD

––– Standard HD Patients
––– Cooled HD Patients

Patients

A

B

Figure 2.2: Plots of changes in renal perfusion during standard and cooled HD. Renal perfusion significantly
declined during standard HD but not during cooled HD. Percent of baseline per kidney perfusion before, 3
hours into, and after dialysis, where results are given as average±SEM. (A) In 29 standard HD patients (57
kidneys), the drop in renal perfusion during HD was statistically significant compared with pre- and postHD blood flow values (P<0.005). (B) In 15 standard and cooled HD patients (30 kidneys each), there was
a smaller decline in renal perfusion during cooled HD (not statistically significant) compared with standard
HD.

2.3.2.2 Standard versus Cooled HD
Perfusion was measured in all 15 crossover patients, resulting in 30 paired values
under standard and cooled HD conditions. Average per kidney perfusion dropped to
79.1%±5.3% and 89.2%±5.9% of baseline at peak stress during standard and cooled HD,
respectively (Figure 2.2B). Session-specific, patient baseline-adjusted ANCOVA revealed
that the decline in intradialytic renal perfusion between dialysis treatments was not
different (F(1,57)=1.814; P=0.18). Average per kidney perfusion recovered to 94.3% of
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baseline after both standard and cooled HD. DRP was observed in 20 out of 30 kidneys
(67%) during standard HD and 15 out of 30 kidneys (50%) during cooled HD (not
significantly different). In those kidneys, however, the perfusion decline (37% below
baseline) was the same for both dialysate temperatures.

2.3.3 Relationship to Cardiac Injury
2.3.3.1 Standard HD
A total of 24 out of 29 patients (83%) exhibited MS. The degree of stunning
correlated with DRP (r=-0.33; P<0.05) (Figure 2.3A). The McNemar test showed that
during HD, MS incidence (83%) was significantly higher (P<0.05) than DRP incidence
(65%). Patients without MS were also protected from HD-induced DRP, where peak
stress perfusion declined by 4.4%±13.5% relative to baseline (not statistically significant).
This change in perfusion, however, was not significantly different from the 21%±5.0%
drop in the MS patients according to patient baseline-adjusted ANCOVA (F(1,52)=1.575;
P=0.22).

2.3.3.2 Standard versus Cooled HD
MS was observed in 13 out of 15 (87%) and 11 out of 15 (73%) patients during
standard and cooled HD, respectively (not significantly different), where DC reduced,
increased, and had no effect on the number of stunned myocardial segments in eight,
five, and two patients, respectively. Although the degree of cardiac injury and severity of
renal insult were not associated during standard HD, they were negatively correlated
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during cooled HD (r=-0.36; P<0.05) (Figure 2.3B). For both HD subgroups, patients
without MS experienced milder DRP.

Standard HD
•○ –––
––– Cooled HD

B

A

Figure 2.3: Plots of changes in renal perfusion versus the number of stunned myocardial segments during
standard and cooled HD. Decreased renal perfusion was associated with an increased number of stunned
myocardial segments during standard and cooled HD. Change in per kidney perfusion from baseline to
peak stress (i.e., 3 hours into dialysis) versus the number of stunned myocardial segments measured with
echocardiography. The dotted lines represent data trendlines. (A) In 29 standard HD patients (57 kidneys),
there was a correlation between the degree of cardiac injury and severity of renal insult (r=-0.33; P<0.05).
(B) In 15 standard and cooled HD patients (30 kidneys each), there was a correlation between the degree
of cardiac injury and severity of renal insult during cooled HD (r=-0.36; P<0.05) but not during standard HD.
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2.3.4 Relationship to Dialysis Stress Factors
2.3.4.1 Standard HD
Seven out of 29 patients (24%) experienced IDH (symptomatic and drop in systolic
blood pressure (SBP) >200 mmHg). SBP and mean arterial pressure (MAP) dropped
significantly during HD to 88.5% (P<0.005) and 91.2% (P<0.05) of baseline, respectively,
before both recovering to 99% of baseline after HD. Although diastolic BP (DBP) behaved
similarly, the intradialytic change to 95.6% of baseline was not significant. However, no
correlations were found between BP changes and MS development and/or changes in
renal perfusion.
Mean and total UF were associated with DRP (r=-0.31; P<0.05 and r=-0.26;
P=0.05, respectively) and more stunned myocardial segments (r=0.30; P<0.05 and
r=0.27; P<0.05, respectively) (Figure 2.4). DRP (in at least one kidney) and MS occurred
in most patients. Comparing those patients who did experience DRP and stunning with
those who did not, there was an association between patients who were taking β-blockers
and DRP and stunning (r=0.48; P<0.01 for DRP and r=0.54; P<0.005 for MS). Also, there
was a discrepancy in patient sex, where the male-to-female ratio was 12:9/7:1 for those
who did/did not experience DRP and 15:9/4:1 for those who did/did not experience MS.

2.3.4.2 Standard versus Cooled HD
Three out of 15 patients experienced IDH during both HD sessions, and ten out of
15 patients experienced an SBP drop (.20 mm Hg) during standard HD compared with
eight out of 15 during cooled HD (not significantly different). Session-specific, patient
baseline-adjusted ANCOVA revealed that BP changes during HD between dialysis
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treatments was not statistically significant (F(1,26)=2.814 and P=0.11; F(1,26)=0.582 and
P=0.45; F(1,26)=0.382 and P=0.54 for SBP, DBP, and MAP, respectively). During
standard HD, changes in SBP and MAP correlated with MS (r=-0.36; P=0.05 and r=-0.38;
P<0.05, respectively). During cooled HD, these associations persisted (r=-.45; P<0.05
and r=-0.43; P<0.05 for SBP and MAP, respectively), and new associations emerged
between BP changes and the number of stunned myocardial segments (r=-0.44; P<0.05
and r=-0.40; P<0.05 for DBP and MAP, respectively) and absolute changes in renal
perfusion (r=0.47; P<0.05 for DBP).
In terms of thermal symptoms, two out of 15 patients reported feeling cold and/or
were shivering during standard HD compared with six out of 15 (two same, four new)
during cooled HD (not significantly different).
During standard HD, UF metrics were not associated with DRP or severity of
myocardial injury. During cooled HD, UF metrics remained uncorrelated to DRP but were
negatively associated with the number of stunned myocardial segments (r=-0.41; P<0.05
for mean and total UF).
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○ ––– Change in Renal Perfusion

• ––– Stunned Myocardial Segments

Figure 2.4: Plot of changes in renal perfusion and the number of stunned myocardial segments versus the
mean UF rate during standard HD. Decreased renal perfusion and an increased number of stunned
myocardial segments were both associated with higher mean ultrafiltration rates during standard HD.
Change in per kidney perfusion from baseline to peak stress (open circles) and number of stunned
myocardial segments (solid circles) versus mean UF rate for 29 standard HD patients (57 kidneys). The
dotted and solid lines represent data trendlines for the renal perfusion and MS data, respectively. The mean
UF rate was associated with a larger drop in renal perfusion from baseline to peak stress (r=-0.31; P<0.05)
and a greater number of stunned myocardial segments (r=0.30; P<0.05).

2.4

Discussion
This study demonstrated that renal perfusion decreased during dialysis, even in the

absence of significant hypotension, contemporaneously with MS. In addition, DRP and
MS were minimized with DC (although not to a statistically significant extent). These
important findings may provide a pathophysiologic explanation and potentially
preventative intervention for the characteristic rapid decline of RRF in patients on HD.
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2.4.1 Renal Perfusion
Although absolute renal perfusion does not directly represent kidney function, it is
a major factor in determining GFR and urine output. As such, perfusion values measured
for this study act as surrogate measures of renal function.

2.4.1.1 Standard HD
Average per kidney perfusion dropped to 81.6% of baseline during HD and 21 out
of 29 patients (72%) experienced intradialytic DRP in at least one kidney. This reduction
in perfusion represents a potential ischemic insult, which is repeated during recurring
dialysis sessions and could result in cumulative renal tissue damage and a subsequent
RRF reduction. This mechanism is reinforced by the inverse correlation between baseline
renal perfusion (RRF surrogate) and dialysis vintage. Perfusion values for patients in our
study (<105 mL/min/100g, average baseline of 33.2±2.9 mL/min/100g) were markedly
reduced compared with normal control (typical range, 200–500 mL/min/100g) and earlier
stage CKD values (approximately 140–300 mL/min/100g) measured in other studies.31-35
Recovery of perfusion to 95%of baseline after HD suggests that HD-induced DRP
resolves after UF ends and hypovolemia is relieved. The role of HD-mediated
hemodynamic instability and transient renal ischemia in progressive RRF decline in
patients on HD has been alluded to previously.10,11,26,36,37 However, this is the first study
to directly measure intradialytic renal perfusion and confirm that DRP represents the first
key step toward characterizing RRF loss in patients on HD.
Patients with ESRD who are undergoing HD three to four times weekly are
subjected to recurrent circulatory stress, suggesting repeated episodes of DRP.
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Interestingly, Ronco et al.38 list the combination of hypoperfusion, prolonged
hypovolemia, and presence of comorbidities as key factors resulting in subclinical,
prerenal AKI. Together with our perfusion results, these aforementioned factors are
present during HD sessions of patients with ESRD. Thus, renal tubular damage due to
repetitive, intradialytic ischemic AKI may contribute to kidney injury resulting in long-term
RRF reduction.

2.4.1.2 Standard versus Cooled HD
DC helped ameliorate HD-induced DRP, where the cooled subgroup experienced
a smaller decline in renal perfusion at peak stress and had fewer kidneys with DRP
compared with the standard subgroup, although neither findings were statistically
significant. Along with other studies that illustrated the protective effects of DC on the
brain25 and heart,24 this study’s findings demonstrate the global hemodynamic effect of
HD and the protective potential of DC.
When considering only kidneys with DRP, the change in perfusion from baseline
to peak stress was the same for both dialysate temperatures. This suggests that although
DC reduces DRP incidence, it does not reduce the magnitude of renal ischemia.
However, because of the difference in the overall number of kidneys with DRP, the decline
in average per kidney perfusion at peak stress was larger (not statistically significant) for
standard HD. These results are consistent with those of a similarly designed study by
Selby et al.,22 which assessed myocardial function. They found that although patients
undergoing standard HD developed more RWMAs compared with cooled HD, the RWMA
magnitude (i.e., percentage shortening fraction) was equal between both HD treatments.

68

2.4.2 Relationship to Cardiac Injury
2.4.2.1 Standard HD
HD causes transient ischemia in multiple vulnerable vascular beds.20,39,40 In the
heart,

demonstrable

injury

manifests

as

MS,41

which

was

measured

with

echocardiography and observed in 83% of patients. In non-stunning patients, intradialytic
perfusion changes were lessened compared with all patients collectively. This reinforces
the notion that MS is a hallmark of HD-induced systemic circulatory stress28,42 and
suggests that its presence potentiates DRP. The magnitude of MS, characterized by the
number of stunned segments, was associated with DRP severity, as well as with higher
mean and total UF. These results suggest that HD-specific factors contributing to DRP
(e.g., aggressive UF, circulating endotoxins, IDH, etc.) are the same as those responsible
for intradialytic myocardial injury.42-44

2.4.2.2 Standard versus Cooled HD
Additional intradialytic cardiac dysfunction may potentiate renal injury. Therefore,
for patients with minimal urine output, RRF preservation could be achieved by lessening
the circulatory stress of HD via hemodynamic-protective strategies. Techniques such as
DC23 and ischemic preconditioning,45 which have shown potential for attenuating the
burden of dialysis upon the heart24,27 and brain,25 may also protect renal parenchyma
from recurring intradialytic ischemic insults.
In this study, DC seemed to help ameliorate intradialytic myocardial injury. Fewer
patients experienced MS during cooled HD and more patients received benefit from the
intervention than harm in terms of severity of myocardial injury (i.e., lowering the number
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of stunned segments with cooling). However, neither of these outcomes were statistically
significant. These findings are consistent with results of similarly designed studies that
characterized and compared myocardial injury during standard versus cooled HD.22,24,27
However, certain shortcomings in the results of those studies (e.g., no difference in left
ventricular ejection fraction between standard and cooled HD groups24,27) and our work
suggests that although DC is a favorable intervention in terms of feasibility and
effectiveness, it may be worthwhile to combine it with other interventions (e.g.,
biofeedback dialysis46-48) to ameliorate HD-induced circulatory stress and myocardial
injury.

2.4.3 Relationship to Dialysis Stress Factors
2.4.3.1 Standard HD
The continual drop in RRF over many HD sessions necessitates more fluid
removal (i.e., higher UF) to account for increased interdialytic hypervolemia. However,
higher UF causes greater hemodynamic stress49 and increases IDH incidence, an
independent predictor of RRF decline.36,50 This coincides with our findings, where DRP
severity was associated with mean and total UF (r=0.31; P,0.05 and r=0.26; P=0.05,
respectively), suggesting that UF-induced ischemic injury may be a key factor in
progressive RRF loss in patients on HD. This establishes a vicious cycle of HD-induced
RRF decline, followed by a necessitated increase in UF, followed again by RRF decline,
in keeping with the observed rapid decline shortly after HD initiation.
RRF declines faster with HD compared with peritoneal dialysis. 19,26 Although
factors such as more gradual shifts in volume and higher biocompatibility play a role in
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greater RRF preservation in peritoneal dialysis relative to HD,51 another key element is
dialysis-induced MS as a marker of global circulatory stress. MS incidence is much lower
in peritoneal dialysis52 compared with HD, suggesting renal perfusion could be better
maintained during treatment and long-term RRF loss may be slowed as a result.
The observed renal hemodynamic response of patients to HD-induced circulatory
stress was heterogenous, similar to other studies of the heart43 and brain.53 Most patients
exhibited DRP, but some instead demonstrated increased perfusion. Although the cause
of this heterogeneity in response is unknown, it is well recognized54 and likely due to the
status of patients’ circulatory compensatory mechanisms. Most patients on HD have
impaired compensatory mechanisms (chronotropic incompetence,55,56 β-blocker use,57
reduced baroreflex sensitivity54), increasing their vulnerability to UF-induced hypovolemia
and IDH, whereas patients with more intact mechanisms are better able to compensate
for HD-induced circulatory stress. In addition, CKD-related factors, such as increased fluid
volume retention, altered sympathetic nervous system activity, endothelial dysfunction,
oxidative stress, inflammation, and increased arterial stiffness, may contribute to varying
BP response to circulatory stress.58 This may be why no association was observed
between BP changes and MS development and/or changes in renal perfusion, despite
significant declines in intradialytic SBP and MAP.
There was an association between MS and DRP, and patients taking β-blockers
(but not other antihypertensives). The blockade of b-adrenergic receptors in the heart
may weaken compensatory mechanisms to offset HD-induced circulatory stress. This
mechanism is unique to β-blockers57 and likely the cause of the observed correlation.
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The discrepancy in sex between patients who did versus did not experience MS
and DRP was apparent in another study that examined HD-induced myocardial injury,42
where the male-to-female ratio was 28:17 for patients who exhibited RWMAs and 19:6
for those who did not. In a study assessing stress cardiomyopathy (i.e., acute emotional
stress leading to MS), 95% of patients were female.59 The authors cite several studies on
myocardial injury with similar sex-related trends, but the biologic mechanisms behind this
discrepancy are unknown.

2.4.3.2 Standard versus Cooled HD
DC did not demonstrate any statistically significant benefit in terms of controlling
intradialytic BP compared with standard HD. However, patients were not subjected to
continuous BP monitoring but only episodic checks (e.g., imaging timepoints). It is
therefore entirely possible that there were BP differences between standard and cooled
HD that could not be assessed. Also, DC has other effects to improve response to
ischemic injury that go beyond just increasing peripheral vasoconstriction to limit
hypotension60 (e.g., increasing ischemic tolerance with moderate hypothermia and effects
on the splanchnic circulation helping to support circulatory volume 61,62). In addition,
changes in SBP, DBP, and MAP were variably associated with MS and renal perfusion
changes for standard and cooled HD. The combination of impaired compensatory
mechanisms and increased BP variability may be the cause of these inconsistent findings.
During cooled HD, correlations between renal perfusion and UF were abolished,
whereas correlations between myocardial injury and UF were reversed. Although these
findings may have been because of a lower relative sample size, they support the idea
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that DC better maintains hemodynamic stability during UF.63,64 Therefore, HD
effectiveness could be improved by using DC to more easily achieve patient-specific UF
requirements.
Four out of 15 patients (27%) were shivering and/or reported feeling cold only
during cooled HD. Other studies found similar22,65 and higher63 temperature-related
symptom incidence. Jefferies et al.27 used patient-individualized body temperature
dialysate (i.e., 0.5°C below core temperature) to improve DC tolerability, where only one
out of 11 patients reported cold-related symptoms. This individualized intervention was
subsequently applied to a larger cohort of 73 patients, with no cooling-related adverse
events reported.24,25

2.4.4 Limitations
This early phase study has several limitations. Patients received a radiation dose
of approximately 8 mSv during each CT perfusion scan. Considering that radiationinduced cancer manifestation typically takes decades,66 and HD patients are generally
older and have a low five-year survival rate,67 patients’ lifespans are not expected to be
affected in any significant way. In addition, only patients with urine output <250 mL/24
hours were examined to limit contrast-induced nephropathy. As a result, the study
focused on patients with low baseline RRF, and this group may be predisposed to
ischemic injury. However, this was proof-of-principle work and further studies are needed
in patients with higher RRF, including patients on incident HD.
There appeared to be no significant artifactual effect of contrast media on renal
perfusion. First, using further exposure to contrast, we demonstrated almost complete
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recovery in average perfusion after HD. Second, contrast agent administration was low
risk (low intravenous dose). Third, crossover experiment patients underwent the same
HD treatments but exhibited improved renal hemodynamics with DC (despite identical
contrast exposure). In addition, we have previously demonstrated testosteronedependent reduction in renal perfusion, with recovery after discontinuation (using the
same small contrast load).35
These were pilot experiments with a modest total sample size of 29 patients. Thus,
generalizing the findings to the general population should be withheld until a larger,
randomized, controlled trial is conducted. However, these experiments included detailed,
multimodal imaging measurements, where both inter- and intra-patient variations were
assessed. Further studies are required to examine the direct effects of standard and
cooled HD upon renal perfusion in individuals with higher RRF, and to longitudinally follow
patients on incident HD with respect to declining RRF.

2.5

Conclusion
In conclusion, recurrent HD-induced renal ischemia lays the groundwork toward

pathophysiologically explaining the previously observed relationship between time spent
on dialysis and declining RRF. In addition, although amelioration of the decline in renal
perfusion by DC did not reach statistical significance, this intervention, which has already
been applied in the protection of the brain and heart from HD-induced injury, may provide
protection from recurrent kidney injury.
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CHAPTER 3
3

Exploring the Link between Hepatic Perfusion and Systemic Endotoxemia in
Hemodialysis Patients
The liver normally receives and clears gut-derived endotoxin but hemodialysis

patients have elevated levels of circulating endotoxin. We used CT perfusion imaging to
assess whether hemodialysis-induced circulatory stress disrupts hepatic perfusion and
function, which could negatively affect the liver’s control of endotoxemia.
The contents of this chapter were adapted from an original research manuscript
entitled “Exploring the Link between Hepatic Perfusion and Systemic Endotoxemia in
Hemodialysis Patients: A Randomized Crossover Study”, which was submitted for
publication in Kidney International in 2020 and co-authored by Raanan Marants, Elena
Qirjazi, Fiona Li, Ka-Bik Lai, Cheuk-Chun Szeto, Philip Li, Ting-Yim Lee and Christopher
McIntyre.

3.1

Introduction
Hemodialysis (HD) induces circulatory stress which causes mesenteric ischemia,

leading to disrupted gut mucosal structure and function.1,2 The resulting increase in
translocated endotoxin (gut-derived proinflammatory mediators) correlates with a
multitude of hemodynamic and cardiovascular complications.3 The liver normally receives
endotoxin from the gut via portal vein blood4 and under healthy conditions, clears it before
it reaches systemic circulation.5 However, increased endotoxin has been found in HD
patients compared to the general population and to early stage chronic kidney disease
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(CKD) patients,3 suggesting that HD may disrupt liver hemodynamics and function,
allowing more gut-derived products to reach the systemic circulation.
Multiple organs develop subclinical ischemia due to intradialytic circulatory stress.6
Functional imaging studies in the heart,7,8 brain9 and kidneys10 have demonstrated these
ischemic insults can be attenuated using dialysate cooling (DC),11 providing intradialytic
hemodynamic protection and minimization of chronic organ dysfunction. However, the
liver’s dual blood supply may allow it to potentially respond differently to HD-induced
circulatory stress.12 Previous work by our group and others has shown that liver
hemodynamics and water content are not significantly affected by HD.12-14 Even so, these
studies have not assessed changes in the fractional supply (from portal vein or hepatic
artery) and how it is related to endotoxemia in HD patients, or the effect of potentially
protective interventions.
Therefore, we conducted an exploratory study of liver perfusion and excretory
function using computed tomography (CT) perfusion imaging to measure hepatic arterial
and portal venous blood flow derived separately from the hepatic artery and portal vein,
respectively, during HD. By assessing intradialytic hepatic perfusion and function, we
aimed to test the hypothesis that HD disrupts liver hemodynamics and drives
endotoxemia. In addition, we intended to explore whether DC ameliorates HD-induced
changes in liver hemodynamics and limits systemic exposure to endotoxin.
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3.2

Methods

3.2.1 Patients
Patients from the London Health Sciences Centre Regional Renal Program
(London, Ontario, Canada) were enrolled in the study after giving informed consent. Adult
patients with HD vintage ≥3 months and low residual renal function (<250 mL/day to limit
any potential effects of contrast-induced nephropathy) were eligible. Major exclusion
criteria included: chronic liver or intestinal disease (excluding irritable bowel syndrome),
previous liver transplant or resection, trans-jugular portosystemic shunt insertion, active
infection/malignancy, current or planned pregnancy, breast feeding, uncontrolled
diabetes mellitus (defined as recorded hypoglycemia during HD within the last 2 months)
or known allergy to iodinated contrast agent.

3.2.2 Study Design
In this crossover study, patients underwent one standard (36.5°C) and one cooled
(35.0°C) dialysate temperature HD session. Other than dialysate temperature, sessions
were identical. The session order was randomly assigned, with patients acting as their
own controls. The randomization list (in blocks of four) was generated by a London Health
Sciences Centre Kidney Clinical Research Unit medical statistician and revealed to the
investigator for allocating subjects to the appropriate study group. A washout period ≥7
days between sessions was scheduled to ensure no significant carry-over effects.15
During these sessions, we collected baseline characteristics and blood work, assessed
hepatic function (clearance of indocyanine green), and acquired CT liver perfusion
imaging. This was a single-blinded study, where patients, HD unit staff and the
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investigator were not blinded to the intervention, but imaging analysis was performed with
the operator blinded to allocation.
This study was approved by the University of Western Ontario Health Sciences
Research Ethics Board and was conducted in compliance with the approved protocols,
Good Clinical Practice Guidelines, the Declaration of Helsinki, and all applicable
regulatory requirements. The study was registered at ClinicalTrials.gov (NCT02997774).

3.2.3 CT Perfusion Imaging
CT liver perfusion imaging was performed on a GE Healthcare (Waukesha, WI)
Revolution 256-slice CT scanner just before, 3 hours into (i.e., peak intradialytic stress),
and 15 minutes post discontinuation of both HD sessions. Patients were moved to the CT
bed for the intradialytic scan without interrupting HD treatment. Dynamic contrastenhanced CT scanning of a 16 cm section of the abdomen was performed, without breathhold, following iodinated contrast agent injection (at a rate of 5 mL/s, followed by a 30 mL
saline flush). Scan regions were optimized to include as much of the liver as possible by
performing a non-contrast localization scan prior to each CT perfusion scan, and were
divided into 32 slices of 5 mm thickness each. This region was scanned 42 times at 2.8 s
intervals using 120 kV and 22.4 mAs for a duration of approximately 2 minutes. Iopamidol
(Isovue 370, Bracco Imaging) at 1 mL/kg of pre-HD patient weight (up to a maximum dose
of 70 mL) was used as contrast agent in both HD sessions. Image noise was reduced
using 100% ASIR (Adaptive Statistical Iterative Reconstruction, GE Healthcare) and liver
motion from breathing between scans was minimized using non-rigid registration (GE
Healthcare).
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CT Perfusion 4D software (GE Healthcare) was used to analyze the registered
images as follows: aortic and portal venous regions of interest (ROIs) were selected for
generation of arterial and venous input functions, respectively. Next, model-based
deconvolution16 was used to compute liver perfusion and the corresponding hepatic
arterial fraction, yielding total liver, hepatic arterial and portal venous perfusion maps. A
region was then manually drawn in the perfusion maps of each slice to encompass the
liver, where blood flow and blood volume thresholds of 200 mL/min/100g and 80 mL/100g,
respectively (determined from prior sensitivity analysis), were imposed to remove nonparenchymal blood vessels from the region, yielding a liver parenchyma ROI. A ROI sizeweighted average of the resulting perfusion values over all liver-containing slices was
performed to obtain mean values (in mL/min/100g) of total, hepatic arterial and portal
venous perfusion for the whole liver.

3.2.4 Quantification of Perfusion Heterogeneity
Based on previous work,12,13 we hypothesized that HD may cause heterogeneous
redistribution of liver perfusion, despite overall perfusion being maintained (Figure 3.1).
Total liver perfusion heterogeneity was quantified using an in-house MATLAB
(MathWorks, Natick, MA) program based on an algorithm developed by Brooks and
Grigsby.17 For this work, the algorithm quantified the magnitude of perfusion gradation
between all pixel-pair combinations in all liver ROIs.
A ROI size-weighted average of the heterogeneity values over all the ROIs was
performed to obtain a mean perfusion heterogeneity value for the whole liver. A summary
of this procedure is presented in Figure 3.2.
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A

B

Figure 3.1: Insensitivity of global mean to changes in spatial perfusion heterogeneity visualized with hepatic
perfusion maps. Total liver perfusion at baseline (A) and 3 hours into hemodialysis (B) for a patient. Liver
parenchyma is outlined with dotted contours. Despite there being no measurable change in average liver
perfusion between the two time-points, liver perfusion heterogeneity increased by approximately 25%.
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Figure 3.2: Theoretical basis of heterogeneity quantification algorithm and application of the algorithm in
this study’s workflow. The heterogeneity quantification algorithm computes the magnitude of pixel intensity
(e.g., perfusion) gradation between all pixel-pair combinations of the liver in every slice. An example of
heterogeneity quantification for a single pixel-pair (pixels 1 and 2, with intensities of I1 and I2, respectively,
separated by distance R) is shown in the case of (A) low, (B) medium, and (C) high heterogeneity. (D) Plot
of pixel intensity change from I1 versus distance along R for case A, B, and C. (E) Following the generation
of liver perfusion maps, manually drawn regions of interest were used to segment the liver parenchyma for
all relevant slices. Next, the heterogeneity quantification algorithm was applied (red arrows) to all non-zero
pixel-pairs within each resulting region, yielding a perfusion heterogeneity value for each region (i.e., for
each slice). A region of interest size-weighted average of the heterogeneity values over the selected slices
was performed to obtain a mean perfusion heterogeneity value for the whole liver.

3.2.5 Assessment of Hepatic Excretory Function
Indocyanine green (ICG) is a synthetic dye that is solely taken up by hepatocytes
and excreted in bile,18 where ICG clearance from blood reflects excretory liver function.
Pulsed-dye densitometry (PDD; DDG devices, Nihon Kohden, Japan) provides a realtime, non-invasive measurement of blood ICG concentration using optical light at two
wavelengths: 805 nm for peak optimal ICG absorption and 890 nm for minimal
absorption.19 Detection of ICG in the blood is based on the fractional change in optical
absorption between the two wavelengths, where heartbeat-induced blood vessel
pulsations lead to optical path length changes.20 As a result, PDD measures ICG
clearance from blood, which reflects excretory liver function. While ICG has historically
also been used to assess liver blood flow, this application has methodological
challenges21,22 and was forgone in favor of using CT perfusion imaging in this work.
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PDD was acquired for approximately 15 minutes following a single ICG bolus
injection through a peripheral cannula by attaching a finger probe to the patient,
measuring ICG concentration in blood over time with every heartbeat. These
measurements were performed just before and 3 hours into every HD session. A
biexponential fit, based on an open two-compartment model of ICG uptake and excretion,
was applied to the data in order to extrapolate past the 15-minute point and more
accurately determine the clearance.23 The ICG clearance rate (mL/min) was calculated
as the quotient of the ICG dose (mg) and the area under the ICG concentration vs. time
curve (mg∙min/mL).

3.2.6 Quantification of Endotoxin Levels
Serum lipopolysaccharide endotoxin quantification was performed using a Limulus
Amebocyte assay (Cambrex, Verviers, Belgium). Following collection in London, all
serum samples were shipped to and assayed at the Prince of Wales Hospital in Hong
Kong, and endotoxin quantification was performed as described previously24 to ensure
comparability with results generated from our previous studies of endotoxin (all of which
were analyzed in the same lab). Briefly, samples were diluted to 20% with endotoxin-free
water and heated to 70°C for 10 minutes to inactivate plasma proteins. The
manufacturer’s protocol was used to quantify serum lipopolysaccharide. Samples with
lipopolysaccharide level below the detection limit of 0.01 endotoxin units (EU)/mL were
taken as 0 EU/mL. Samples were run in duplicate and the background noise was
subtracted.
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3.2.7 Statistical Analysis
Liver perfusion and excretory function were scarcely assessed previously in the
context of HD and insufficient data exist to support performing a meaningful sample size
calculation. This was an initial proof-of-principle study for hypothesis generation, with a
sample size not powered for inferential statistical analysis. However, the sample size is
comparable with previously published norms7,10,25,26 and recommendations,27,28 and was
chosen on a partly pragmatic basis.
All statistical analyses were performed using SPSS, version 25.0 (IBM, Chicago,
IL). Repeated measure ANOVA with Bonferroni-corrected post-hoc t-tests, and patient
baseline-adjusted ANCOVA, were used to detect differences between groups and
subgroups. Pearson’s product-moment correlation coefficient was used to determine
associations between variables, and McNemar’s test was used to detect differences
between proportions. Two-tailed P values <0.05 were considered statistically significant.
Results are presented as mean ± standard error of the mean, unless otherwise specified.

3.3

Results

3.3.1 Clinical Characteristics of Study Population
Sixteen patients (ten male) aged 45-84 years were enrolled in this study. One
patient was unable to return for the second session and was excluded from analysis.
Fifteen patients completed the study, and Table 3.1 presents the summary of patient
baseline characteristics, including age, sex, HD treatment details and comorbidities. This
patient cohort was the same as the project 1 cooled HD cohort.
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Table 3.1: Baseline characteristics of second project study population.
Mean (Range)a

Characteristics
n

15

Age

63 (45–84)

Men, n (%)

10 (67)

Dialysis Vintage (years)

3.0 (0.8–25.4)

Length of Hemodialysis Session (hours)

3.6 (3.1–4.2)

Ultrafiltration (mL/kg)

23.3 (6.1–40.9)

Coronary Artery Disease, n (%)

5 (33)

Congestive Heart Failure, n (%)

3 (20)

Peripheral Vascular Disease, n (%)

3 (20)

Diabetes, n (%)

9 (60)

Hypertension, n (%)

14 (93)

aUnless

otherwise specified.

3.3.2 Hepatic Perfusion
Average baseline total liver perfusion was 82.7±3.7 mL/min/100g, with an average
hepatic arterial fraction of 22.6%. Average total liver, hepatic arterial and portal venous
perfusion changed to 106.7%±5.4%, 101.3%±11.2% and 111.1%±5.1% of baseline at
peak HD stress, and 105.6%±3.7%, 102.7%±9.6% and 109.1%±6.0% of baseline after
HD, respectively. None of these changes were statistically significant, but portal vein
perfusion showed the greatest trend towards changing during HD (P=0.14, Figure 3.3A).
Perfusion heterogeneity increased by 12.5%±4.4% (P=0.038) and 17.8%±3.7%
(P=0.001) with respect to baseline during and after HD, respectively (Figure 3.4A). There
91

was an association between intradialytic changes in perfusion heterogeneity and total
liver perfusion (r=0.70, P=0.003).

Percent of Baseline Values

A

B

Figure 3.3: Plots of relative hepatic perfusion to baseline before, 3 hours into and after standard HD (A) and
cooled HD (B). There were no significant changes in total liver, hepatic artery and portal vein perfusion over
the course of either standard or cooled HD. However, portal vein perfusion demonstrated the greatest trend
towards increasing during standard HD (P=0.14). Results are given as average ± standard error of the
mean (SEM).

3.3.3 Hepatic Excretory Function
The ICG clearance rate dropped by 14.5%±5.3% (P=0.016) with respect to
baseline during HD (Figure 3.4A). Changes in ICG clearance rate correlated with changes
in total liver perfusion (r=0.55, P=0.034) and showed an associative trend with changes
in perfusion heterogeneity (r=0.49, P=0.06) during HD. See Appendix A for a summary of
relative changes in liver enzymes from pre- to post-HD (Table A1).
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3.3.4 Endotoxin Levels
Average baseline endotoxin levels were 0.292±0.0156 EU/mL and correlated with
dialysis vintage (r=0.58, P=0.024). Endotoxin increased by 19%±9.1% (P=0.15) and
28.4%±9.9% (P=0.037) with respect to baseline during HD and after HD, respectively
(Figure 3.4A). Increased post-HD endotoxin correlated with the presence of congestive
heart failure (r=0.52, P=0.046) but not with ultrafiltration (UF) metrics (UF volume, mean
and maximum UF rates).

Percent of Baseline Values

A

B

Figure 3.4: Plots of relative endotoxin levels, ICG clearance rate, and hepatic perfusion heterogeneity to
baseline before, 3 hours into and after standard HD (A) and cooled HD (B). ICG clearance rate (P=0.016)
and perfusion heterogeneity (P=0.038) significantly changed during standard HD and endotoxin levels
(P=0.037) significantly changed after standard HD. None of these changes were statistically significant with
cooled HD. Results are given as average ± standard error of the mean (SEM).
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3.3.5 Effects of Dialysate Cooling
In contrast to standard HD, changes from baseline of all hepatic perfusion, hepatic
excretory function, and endotoxin data during and after cooled HD were not statistically
significant (Figures 3.3B and 3.4B). Although DC appeared to mitigate the hemodynamic
and functional HD-induced changes that were observed for standard HD, sessionspecific, patient baseline-adjusted ANCOVA revealed that the changes in perfusion (total,
hepatic arterial, portal venous), perfusion heterogeneity, ICG clearance rate, and
endotoxin level between dialysis treatments were not statistically significantly different.

3.3.6 Intradialytic Blood Pressure and Adverse Events
Three patients experienced intradialytic hypotension (IDH) during both HD
sessions, while ten experienced a systolic blood pressure drop >20 mm Hg during
standard HD compared with eight during cooled HD (P=0.69). Intradialytic changes in
blood pressure between dialysis treatments were not statistically significant according to
session-specific, patient baseline-adjusted ANCOVA (F(1,26)=2.814 and P=0.11;
F(1,26)=0.582 and P=0.45; F(1,26)=0.382 and P=0.54 for systolic blood pressure,
diastolic blood pressure, and mean arterial pressure, respectively). During standard HD,
increased endotoxin levels demonstrated an associative trend with the maximum
reduction in mean arterial pressure (r=0.47, P=0.08). In terms of adverse events from DC,
only thermal symptoms were reported: six patients reported feeling cold or experienced
shivering during cooled HD, compared to two during standard HD (P=0.13).
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3.3.7 Exploratory Analysis of Hepatic Perfusion Heterogeneity
Patients were divided into those with and without an increase in total liver perfusion
heterogeneity during standard HD (defined as an increase in perfusion heterogeneity at
peak dialytic stress ≥2 SEM of the patient group), yielding eight and seven patients with
and without increased perfusion heterogeneity, respectively.
The subgroup of patients with increased perfusion heterogeneity had improved
intradialytic ICG clearance (average decrease from baseline of 9.9%) and better
maintenance of post-HD endotoxin levels (average increase from baseline of 18.8%)
compared to the subgroup without increased perfusion heterogeneity (average decrease
in ICG clearance from baseline of 18.2%, average increase in endotoxin levels from
baseline of 39.3%). In addition, the subgroup of patients with increased perfusion
heterogeneity received less benefit from DC in terms of the aforementioned functional
measures (average decrease in ICG clearance from baseline of 10.9%, average increase
in endotoxin levels from baseline of 8.4%), as compared to the subgroup without
increased perfusion heterogeneity, who did appear to benefit from DC (average increase
in ICG clearance from baseline of 2.1%, average increase in endotoxin levels from
baseline of 1.7%).
Nevertheless, subgroup-specific, patient baseline-adjusted ANCOVAs were run
for the aforementioned subgroup comparisons, revealing that none of the changes in ICG
clearance or endotoxin levels between subgroups were significantly different. A summary
of these findings, as well a comparison to these results for all patients collectively, is
shown in Figure 3.5.
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Percent of Baseline Values

A

B

Endotoxin Levels
All Patients (n = 15)
Patients with Increased Perfusion Heterogeneity (n = 8)
Patients without Increased Perfusion Heterogeneity (n = 7)

ICG Clearance Rate
All Patients (n = 15)
Patients with Increased Perfusion Heterogeneity (n = 8)
Patients without Increased Perfusion Heterogeneity (n = 7)
Figure 3.5: Plots of relative endotoxin levels and ICG clearance rate to baseline before, 3 hours into and
after standard HD (A) and cooled HD (B) for patients with (n=8) and without (n=7) increased perfusion
heterogeneity, and all patients (n=15). Increased perfusion heterogeneity during HD seemed to affect
endotoxin levels and ICG clearance rate. (A) For standard HD, patients with increased perfusion
heterogeneity appeared to have better intradialytic ICG clearance and improved maintenance of post-HD
endotoxin levels compared to the subgroup of patients without increased perfusion heterogeneity (not
statistically significant). (B) For cooled HD, the opposite was true (not statistically significant).

3.4

Discussion
This is the first study to demonstrate that redistribution of liver perfusion and

attenuation of hepatic function occur together during HD. In addition, this is the first time
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DC has been applied to prevent liver injury and endotoxemia. The important findings of
this work may help to better understand how HD negatively affects the liver and results in
the exacerbation of endotoxemia in maintenance HD patients, while also providing
preliminary evidence for a potentially preventative intervention to limit systemic toxin
exposure during HD and over the long-term.

3.4.1 Effects of Hemodialysis on Hepatic Perfusion, Hepatic Excretory Function and
Endotoxemia
In this work, hepatic perfusion was measured using CT perfusion imaging, an
approach which has been previously validated.29 Overall liver perfusion did not
significantly change during HD. While there is a paucity of data regarding intradialytic liver
perfusion measurements, our findings are consistent with prior work.12,13 These findings
likely resulted from the liver’s dual blood supply system which may have protected it from
subclinical perfusion shifts associated with reduction in hepatic arterial flow,30 although
further work is needed to elucidate details of this mechanism. In addition, intradialytic
portal vein perfusion showed the greatest trend towards changing, rising to 111% of
baseline during HD. As portal venous blood is toxin-laden,4 this finding suggests that HDinduced circulatory stress may increase endotoxin influx from the gut to the liver following
translocation, and may be responsible for the trend towards increasing endotoxin levels
during HD.
Liver perfusion heterogeneity was also assessed in this study, as significant
perfusion changes may occur in small discrete liver regions and this signal would be lost
if averaged over the entire liver volume (balanced by other areas shunting increased
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blood flow). There are various approaches to quantify medical image heterogeneity (i.e.,
texture analysis31,32), and while each analysis technique has its advantages and
applications, we chose to implement the algorithm developed by Brooks and Grigsby 17
due to its intuitiveness and ease of implementation with respect to our data. This algorithm
yields a single statistic per image, providing a simple, quantitative method of comparing
images based on heterogeneity. We observed with this algorithm a significant increase in
hepatic perfusion heterogeneity during HD. While never studied in the context of HD, liver
perfusion heterogeneity has been assessed for various types of liver injury,33-35
consistently demonstrating a relationship with hepatic injury. In addition, changes in liver
excretory function (i.e., ICG clearance rate) were related to changes in hepatic perfusion
and perfusion heterogeneity in this work.
Previous studies (including in dialysis patients36,37) performed ICG-based
measurements of hepatic function,38 which in this work, was assessed by measuring the
ICG clearance rate with the optical PDD technique. Because clearance of ICG and
endotoxin occurs fully18 and partially39 within hepatocytes, respectively, and given that
our patients had minimal residual renal function and a likely higher reliance on hepatic
clearance, the ICG clearance rate therefore represents a suitable surrogate measure of
hepatic endotoxin clearance.
Excretory liver function significantly declined during HD, as measured with PDDbased ICG clearance. Previous work has demonstrated that decreased ICG clearance
following hepatic injury is linked to increased production of reactive oxygen intermediates
and neutrophil elastase,40 and occurs together with increased expression of endothelin1,41 all of which mediate liver cell injury and/or dysfunction.40,42,43 In addition, endotoxin
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itself has also been shown to induce oxidative stress44,45 and attenuate ICG
clearance.46,47 Raised levels of these and other inflammatory mediators have been
characterized in ESRD and HD patients,3,44,45,48-51 suggesting that the liver is susceptible
to recurrent HD-induced circulatory stress via inflammatory mediators which negatively
affect hepatic function and cause hepatic injury (see Appendix A, Table A1).
We have previously demonstrated that renal perfusion significantly declines at
peak dialytic stress,10 representing repetitive, intradialytic episodes of ischemic acute
kidney injury.52 The potential negative relationship between kidney injury and the liver’s
clearance function has been previously discussed in the context of acute kidney injury53,54
and ESRD,13,55 and may be an important additional factor contributing to HD-induced
hepatic dysfunction and increased endotoxemia.
In this work, endotoxin was quantified using a Limulus Amebocyte assay in a
manner described previously.24 Although the sensitivity of this technique has been
criticized,56 we have taken measures to establish internal consistency of our current
measurements to ensure that our findings were not artefactual. Firstly, serum samples
were collected before, during and after HD, yielding three endotoxin measurements per
patient per study visit. As these samples were stored, shipped, and analyzed identically
to one another, any potential issues with endotoxin quantification methodology would
affect all three samples equally (save for minor fluctuations). Therefore, while the absolute
measures of endotoxin may not be completely accurate, the relative changes in endotoxin
from baseline levels (which we present and focus on) still hold true and provide scientific
value. Secondly, the endotoxin quantification methodology used in this work is the same
as what was done in our group’s previous studies.3,57-59 Given our familiarity and expertise
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with this methodology, along with the convincing, positive results it has enabled us to
produce previously (e.g., endotoxin levels in HD patients correlate with negative clinical
outcomes and reduced survival3), we felt confident applying it to the current study as well.
The baseline endotoxin levels measured in this work (0.29 EU/mL) are consistent
with findings in other studies of dialysis patients.56,60 Endotoxin levels trended towards
increasing during HD, and increased markedly from baseline after HD. This escalation
has been attributed to increased endotoxin translocation from mesenteric injury and
compromised gut mucosal permeability,1,2 which is repeated during recurring dialysis
sessions. This mechanism is reinforced by the strong correlation observed between
baseline endotoxin levels and dialysis vintage. In addition, other than an associative trend
between increased endotoxin levels and maximum reduction in mean arterial pressure
during HD, we did not find evidence of HD-induced circulatory stress (i.e., UF metrics and
IDH) being linked to endotoxemia, differing from the results of other studies.3,59 This
suggests (a) that in our patients, endotoxemia was driven more by liver hemodynamic
and excretory functional changes than by direct effects of circulatory stress (i.e., UF
metrics and IDH), and (b) that more generally, it may be the combination of direct effects
of circulatory stress together with changes in hepatic hemodynamics and excretory
function which contribute to increased endotoxin levels characteristically seen in HD
patients.
Based on the results of this study (italicized items below), we propose the following
pathway by which HD perpetuates endotoxemia in ESRD patients:
1: Mesenteric ischemia (due to HD-induced circulatory stress) disrupts gut mucosal
structure and function, and increases bowel wall permeability.
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2: Endotoxin more readily translocates across the intestinal barrier.
3: More endotoxin arrives to the liver from the gut via portal vein perfusion, which trends
towards increasing during HD.
4: Decreased ICG clearance rate during HD represents compromised hepatic excretory
function, likely due to increasing levels of endotoxin and other inflammatory mediators.
5: Further increase in post-HD endotoxin levels, likely resulting from the combination of
more endotoxin arriving to the liver and lowered hepatic clearance function.
6: Recurrent cycles over many HD sessions lead to higher circulating endotoxin levels in
ESRD patients.

3.4.2 Initial Description of Dialysate Cooling Effects
We demonstrated that DC did not negatively affect liver hemodynamics and
function, or worsen endotoxemia, and may even have helped improve these metrics
compared to standard HD, albeit this was not statistically significant. This is plausible
because cooling potentiates better maintenance of organ perfusion due to peripheral
vasoconstriction,61 increased baroreflex sensitivity variability,62 and reduced IDH.62,63
Also, in the context of therapeutic hypothermia, cooling mitigates organ injury via several
potential mechanisms of action (e.g., reducing inflammation, attenuating oxidative stress,
decreasing free radical production), demonstrating effectiveness in multiple organs.64,65
Therefore, it is reasonable to assume that DC-induced maintenance of liver perfusion and
mitigation of hepatic injury could result in improved control of endotoxin levels. However,
the beneficial changes of DC observed in this study were not statistically significantly
different compared to changes during standard HD, and further work is needed to
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demonstrate the protective potential of DC for preserving hepatic function and mitigating
endotoxemia.
The DC results of this work corroborate with findings of similarly designed studies
assessing myocardial injury7,8,25 and renal ischemia10 during cooled HD. The
effectiveness of DC was not universal in those studies (e.g., no difference in left
ventricular ejection fraction between standard and cooled HD groups, 8,25 no difference
between decreased kidney perfusion between standard and cooled HD groups 10) or in
our work. In addition, four of our 15 patients (27%) experienced cold-related symptoms
(e.g., shivering, feeling cold) during cooled HD only, which is consistent with the incidence
of temperature-related symptoms reported in other studies.7,66,67 These findings suggest
although DC shows promise as an intradialytic intervention, combining cooling with other
interventions (e.g., ischemic preconditioning68,69) and/or implementing other cooling
techniques (e.g., DC based on pre-HD body temperature8,25) may more effectively
ameliorate HD-induced circulatory stress and cooling-related symptoms.

3.4.3 Exploratory Analysis of Hepatic Perfusion Heterogeneity
Patients were divided into those with and without an increase in total liver perfusion
heterogeneity during HD (due to well described association with hepatic injury33-35).
Patients with increased perfusion heterogeneity had smaller relative increases in
endotoxin levels post-HD and smaller relative decreases in ICG clearance during HD
compared to patients without increased heterogeneity. Although these findings were not
statistically significant (potentially due to small subgroup sizes) they suggest that
increased heterogeneity may represent protection from hepatic injury, or a consequence
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of it. Mehrabi et al.33 speculated that “increased heterogeneity of liver perfusion …
probably can be seen as a basic physiological reaction to trauma”, which in this context
is HD-induced circulatory stress. Regardless of interpretation, increased heterogeneity
was linked to increased perfusion, suggesting that higher levels of perfusion are required
to redistribute blood flow and to increase perfusion heterogeneity. More studies are
needed to better elucidate the relationship of perfusion heterogeneity with liver function
during HD.
DC had intriguing and potentially important effects on patients when split into those
with and without an increase in total liver perfusion heterogeneity during HD, although
these results did not reach statistical significance. Patients with increased perfusion
heterogeneity seemed to receive less benefit from cooling in terms of controlling
endotoxin levels and maintaining ICG clearance. However, patients without increased
heterogeneity appeared to benefit greatly from DC. As postulated earlier, it may be that
increased intradialytic liver perfusion heterogeneity represents some form of intrinsic
hepatic functional protection, and since cooling reduces the changes in heterogeneity, it
acts to effectively attenuate this heterogeneity-based protective effect. Interestingly, DC
and increased perfusion heterogeneity may be two competing protective effects which
work to preserve liver function and limit endotoxemia.

3.4.4 Limitations
There are several limitations associated with this early phase study. First, our study
did not examine the relationship between changes in ICG clearance and cardiac output
during HD, which may have had significant effects on hepatic function measurements.
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Second, this was a pilot study with a limited sample size of 15 patients, and generalization
of findings should be withheld until a larger, randomized controlled trial is performed.
However, this study incorporated imaging and functional measurements for assessment
of both inter- and intra-patient variations. Third, only patients with low baseline renal
function (urine output <250 mL/24 hours) were assessed to minimize the risk of contrastinduced nephropathy damaging significant residual renal function, and this patient group
may be predisposed to hepatic injury. However, this was a proof-of-principle study, and
future experiments are required to examine the direct effects of standard and cooled HD
upon endotoxemia and liver hemodynamics in individuals with higher residual renal
function, and to longitudinally follow patients new to HD with respect to increasing
endotoxin levels.

3.5

Conclusion
In summary, HD-induced circulatory stress resulted in redistribution of liver

perfusion and attenuation of hepatic excretory function. Endotoxin levels peaked after
HD, and higher endotoxin levels in end-stage renal disease patients may result from the
combination of two intradialytic effects: decreased hepatic clearance of endotoxin, and a
trend towards increased toxin-laden portal vein perfusion to the liver. In addition, although
mitigation of endotoxin via improved maintenance of hepatic perfusion and function with
DC did not reach statistical significance, this intervention, which has already been applied
in the protection of the brain, heart and kidneys from HD-induced injury, warrants further
study on its protective effects from endotoxemia.
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CHAPTER 4
4

Measuring Glomerular Filtration Rate in End-Stage Renal Disease Patients on
Hemodialysis using CT Perfusion Imaging
Accurate assessment of residual renal function in end-stage renal disease patients

is critical for adjusting the hemodialysis prescription but no clinical method exists currently
which can accurately and efficiently measure glomerular filtration rate in these patients.
Using CT perfusion imaging, we developed and applied a novel glomerular filtration rate
measurement approach in hemodialysis patients which has the potential to become an
accessible clinical renal function assessment technique in this population.
The contents of this chapter were adapted from an original research manuscript
entitled “Measuring Glomerular Filtration Rate in End-Stage Renal Disease Patients on
Hemodialysis using CT Perfusion Imaging”, which was submitted for publication in
Radiology in 2020 and co-authored by Raanan Marants, Christopher McIntyre, and TingYim Lee.

4.1

Introduction
The current clinical protocol for measuring kidney function (i.e., glomerular filtration

rate, GFR) in end-stage renal disease (ESRD) patients on hemodialysis (HD) is
cumbersome, time-consuming and inaccurate.1-3 This is problematic because adjusting
HD prescription based on changes in a patient’s residual renal function (RRF) is an
important aspect of clinical care4 that is difficult to address and often disregarded.1,3 If it
were possible to readily and rapidly obtain accurate GFR measurements, RRF-based HD
prescription adjustments may have yielded better outcomes for ESRD patients.
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Presently, there is no way to accurately measure GFR in ESRD, which is
commonly assessed using population-based equations (using demographic information
and serum creatinine/urea levels) or urine/plasma sampling of endogenous/exogenous
markers.2 While these approaches represent the current gold standard in nephrology
practice, they have important limitations to consider,2 including:
•

Population-based equation accuracy decreases with kidney disease progression

•

Endogenous marker levels directly affected by HD and fluctuate during HD cycle

•

Impossible to perform single-kidney GFR assessment
These limitations may be overcome with imaging-based GFR measurement. While

many previous studies have explored such methodologies in animal and human
subjects,5,6 these techniques have never been applied to ESRD and/or HD patients. In
this technical development, we propose using computed tomography perfusion (CTP)
imaging to measure GFR in HD patients. If appropriately implemented, we believe that
CTP imaging has the potential to become an accessible clinical GFR measurement
method in ESRD patients on HD, providing a rapid, reliable and accurate measurement
of kidney function.

4.2

Methods

4.2.1 Patients and Study Design
Patients from the London Health Sciences Centre Regional Renal Program
(London, ON) were enrolled after giving informed consent. Adult patients with HD vintage
≥3 months and low RRF (<250 mL/day to limit any potential effects of contrast-induced
nephropathy) were eligible. Exclusion criteria included: active infection/malignancy,
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pregnancy, breast feeding, planned pregnancy, diabetic with hypoglycemia during HD
within the last 2 months or known allergy to iodinated contrast agent.
In this crossover study, patients underwent one standard (36.5°C) and one cooled
(35.0°C) dialysate temperature HD session. During both sessions, HD was administered
using a Fresenius 5008 machine (Waltham, MA) with a high-flux polysulfone membrane.
Session order was randomly assigned, with patients acting as their own controls. A
washout period ≥7 days between sessions was scheduled to prevent significant carryover effects. During each session, we collected baseline characteristics and blood work,
and acquired CT renal perfusion imaging. Patients, hemodialysis unit staff and the
investigator were not blinded to the intervention, but imaging analysis was performed with
the operator blinded to allocation. This study was approved by the University of Western
Ontario Health Sciences Research Ethics Board and was conducted in compliance with
the approved protocol, Good Clinical Practice Guidelines and all applicable regulatory
requirements.

4.2.2 CT Perfusion Imaging
CT renal perfusion imaging was performed on a GE Healthcare (Waukesha, WI)
Revolution 256-slice CT scanner before, during (i.e., peak intradialytic stress), and after
HD for both sessions. Patients were moved to the CT bed for the intradialytic scan without
interrupting HD treatment. Iopamidol (Isovue 370, Bracco Imaging), at 1 mL/kg of pre-HD
patient weight (up to a maximum dose of 70 mL), was the non-ionic, low-osmolar
iodinated contrast agent used for both sessions.
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Dynamic contrast-enhanced CT scanning of a 16 cm long abdominal region,
selected to include as much of both kidneys as possible, was performed without breathhold following contrast agent injection into an antecubital vein at 5 mL/s injection rate.
The selected region was divided into 32 slices of 5 mm thickness each and scanned 42
times at 2.8 s intervals using 120 kV and 22.4 mAs for a duration of approximately 2
minutes. Image noise was reduced using 100% Adaptive Statistical Iterative
Reconstruction (GE Healthcare). Reconstructed images were co-registered with non-rigid
transformation (GE Healthcare) to minimize kidney misregistration from breathing motion.
The registered images were analyzed with the CT Perfusion 4D software (GE
Healthcare). An aortic region of interest (ROI) was selected for generation of arterial input
function (AIF, Ca(t)) from the registered dynamic images. Next, the AIF was deconvolved
from the time-density curve of each 3⨯3 kidney voxel, Q(t), based on the Johnson-Wilson
model of contrast distribution in kidney7 to compute various functional parameters,
yielding parametric maps of renal perfusion (F) and permeability-surface area product
(PS)8 for all slices containing the kidneys. In the deconvolution process, the parameters
of the Johnson-Wilson model – F, K, k and MTT – were iteratively changed to minimize
the sum of squared deviations of the convolution of the blood flow-scaled impulse residue
function, RF(t), with Ca(t) from Q(t) as shown in Figure 4.1.

4.2.3 GFR Quantification
To improve corticomedullary differentiation for accurate cortical delineation, the
second quarter of the dynamic series CT images (i.e., timepoints 11-21 of 42) were
summed together for each slice. This timepoint range was chosen to maximize contrast
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enhancement in the cortex (i.e., cortical phase), which occurs in early timepoints (e.g., 110) for healthy kidneys but occurs later in diseased kidneys.9,10 Next, a dynamic threshold
was applied separately for each slice of each kidney of every patient, and was chosen by
anatomically matching the segmented cortical region to the contrast-enhancement cortex
of the summed image as closely as possible (see Figure 4.2). This process yielded a
segmented cortical ROI which was superimposed onto the corresponding F and PS
parametric maps for all relevant slices. The GFR was then computed as follows:
K = filtration rate constant, M = pixel mass
F = perfusion, E = extraction efficiency

𝐺𝐹𝑅𝑝𝑖𝑥𝑒𝑙,𝑖 = 𝐾 ∙ 𝑀
𝐺𝐹𝑅𝑝𝑖𝑥𝑒𝑙,𝑖 = (𝐹 ∙ 𝐸) ∙ (𝑉 ∙ 𝐷)
𝐺𝐹𝑅𝑝𝑖𝑥𝑒𝑙,𝑖 = [𝐹 ∙ (1 −

𝑃𝑆
𝑒 − 𝐹 )]

V = pixel volume, D = tissue density

∙ [(𝐴 ∙ 𝑇) ∙ 𝐷]
PS = permeability-surface area product
A = pixel area, T = slice thickness

𝐺𝐹𝑅𝑠𝑙𝑖𝑐𝑒 = ∑

𝑁𝑝
𝑖=1

𝐺𝐹𝑅𝑝𝑖𝑥𝑒𝑙,𝑖

𝐺𝐹𝑅𝑘𝑖𝑑𝑛𝑒𝑦 = 𝐵𝑆𝐴 ∙ ∑

𝑁𝑠

Np = number of cortical pixels in image slice
Ns = number of image slices in kidney

𝐺𝐹𝑅𝑠𝑙𝑖𝑐𝑒,𝑖

𝑖=1

BSA = 1.73m2 / patient’s body surface area

For this work, A = (0.88 mm)2, T = 5 mm and D = 1.050 g/mL11 in all cases.
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F ∙ Ca (t)
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K

⊗

=
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Figure 4.1: GFR measurement by analyzing CTP images with a tracer kinetic model. (A) Schematic of
Johnson-Wilson model applied to the glomerular capillaries (red region) and Bowman’s capsule (yellow
region) in the kidney. Contrast is delivered by perfusion (F) to the glomerulus and in the mean transit time
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(MTT) it takes to travel from the afferent arteriole to the efferent arteriole, it is filtered through the glomerular
barrier into the Bowman’s capsule. The filtration process is governed by the influx (K) and efflux (k) rate
constant. (B) From the dynamic series CT images, the arterial input function, Ca(t), and each 3⨯3 pixel
tissue time-density curve in the kidney, Q(t), were obtained. Ca(t) is deconvolved from Q(t) to calculate the
flow-scaled impulse residue function, RF(t), based on the Johnson-Wilson model, yielding parametric maps
(e.g., perfusion, permeability-surface area product) which are used to compute GFR as explained in the
text. The ⊗ symbol is the convolution operator.

4.2.4 Statistical Analysis
GFR has seldom been measured in HD patients previously; inadequate data exist
for a meaningful sample size calculation. This was an initial proof-of-principle study to
explore the feasibility of our methods, with a sample size not powered for inferential
statistical analysis
Statistical analysis was performed using SPSS, version 25.0 (IBM, Chicago). Data
were analyzed using primarily non-parametric statistical tests. Differences between
groups and associations between variables were assessed using the Wilcoxon signedrank test and the Spearman rank-order correlation coefficient, respectively. Associations
between GFR and perfusion data were assessed (on a per kidney basis) using the
Pearson product-moment correlation. Two-tailed P values <0.05 were considered
statistically significant. Results are presented as the mean ± standard error of the mean
(SEM), unless otherwise specified.
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Figure 4.2: Image processing steps for CTP-based GFR measurement. (A) Average of entire dynamic
series CT images with poor corticomedullary differentiation. (B) Summation of cortical phase timepoints
(i.e., second quarter of dynamic series CT images) only, demonstrating a minor yet noticeable improvement
in corticomedullary differentiation. (C) Application of dynamic threshold (anatomically matching the
segmented cortical region to the contrast-enhanced cortex of the summed image as closely as possible),
(D) allowing for creation of cortical region masks. (E) Cortical region masks were superimposed onto the
perfusion and permeability-surface area product map, (F) yielding values that were used to calculate GFR
(as described in section 4.2.3).

4.3

Results
Of the sixteen patients enrolled, ten were excluded from the analysis to measure

GFR because either one or both kidneys was not completely captured in the CTP
scanning. Six patients completed the study and were analyzed. A summary of patient
baseline characteristics is presented in Table 4.1.
Of the six patients, only one was randomized to receive cooled HD during the first
visit, while the other five all received standard HD during the first visit. Consequently,
analyzing the results based on organizing the patients by HD type (i.e., standard HD or
cooled HD) did not significantly alter any of the relevant findings or conclusions of this
work. Therefore, the results will be presented based on organizing the patients by study
visit (i.e., first or second visit). A summary of the patient-specific HD session details is
shown in Table 4.2.
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Table 4.1: Baseline characteristics of third project study population.
Mean (Range)a

Characteristics
n

6

Age

62 (45–84)

Men, n (%)

2 (33)

Dialysis Vintage (years)

3.3 (0.8–25.4)

Length of HD Session (hours)

3.5 (3.0–4.0)

UF (mL/kg)

21.3 (8.6–38.5)

Coronary Artery Disease, n (%)

1 (17)

Congestive Heart Failure, n (%)

1 (14)

Peripheral Vascular Disease, n (%)

2 (33)

Diabetes, n (%)

1 (17)

Hypertension, n (%)

5 (83)

aUnless

otherwise specified.

Table 4.2: Patient-specific HD session details.
Patient
Days Between
HD Type of Visit 1 / 2
Number
Visits

HD Sessions
Between Visits

HD Vintage
(months)

1

Standard / Cooled

14

5

48

2

Standard / Cooled

14

5

14

3

Standard / Cooled

49

20

22

4

Standard / Cooled

35

14

9

5

Cooled / Standard

7

2
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6

Standard / Cooled

7

2

302
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Pre-HD GFR values are presented in Table 4.3. The average baseline left kidney,
right kidney, and total GFR values for the first visit were 2.6±0.9, 1.7±0.5, and 4.3±1.0
mL/min/1.73m2, respectively. The average baseline left kidney, right kidney, and total
GFR values for the second visit were 2.6±1.1, 1.5±0.4, and 4.0±1.2 mL/min/1.73m2,
respectively. There were no significant differences between the corresponding GFR
values between the two visits (2.6±0.9 to 2.6±1.1 mL/min/1.73m2 for left kidney GFR,
P=0.917; 1.7±0.5 to 1.5±0.4 mL/min/1.73m2 for right kidney GFR, P=0.075; 4.3±1.0 to
4.0±1.2 mL/min/1.73m2 for total GFR, P=0.345). These findings are summarized in Table
4.3. In addition, Figure 4.3 presents the changes in single-kidney and total GFR over the
course of the two study visits. See Appendix B for a summary of GFR (Table B1),
perfusion (Table B2) and extraction efficiency (Table B3) values for all patients.

Table 4.3: Average pre-HD GFR values. Results are presented for the left kidney, right
kidney, and both kidneys for the first and second study visits.
Mean Baseline GFR ± SEM (mL/min/1.73m2)
Visit 1

Visit 2

Left Kidney

2.6 ± 0.9

2.6 ± 1.1

Right Kidney

1.7 ± 0.5

1.5 ± 0.4

Total

4.3 ± 1.0

4.0 ± 1.2

122

Visit 1

Visit 2

Figure 4.3: Changes in single-kidney and total GFR over the two HD visits, where GFR was assessed
before, during and after HD for each visit. Right kidney, left kidney and total GFR values are represented
by the light gray, dark gray, and black curves, respectively. The average baseline GFR was not significantly
different between the first and second visit for the left kidney (P=0.917), right kidney (P=0.075), and total
GFR (P=0.345). Results are given as average ± SEM (standard error of the mean).

4.4

Discussion

4.4.1 GFR
Among the two visits, average baseline total GFR ranged between 4 and 4.5
mL/min/1.73m2, while average baseline single-kidney GFR ranged between 1 and 3
mL/min/1.73m2. Overall, these values are physiologically reasonable and may accurately
represent true RRF.
Measured GFR trended towards decreasing pre- to post-HD over the course of
both visits. Firstly, These findings coincide with previous work which demonstrated that
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renal function is maximal pre-HD and minimal post-HD.12 Secondly, measured cortical
perfusion (see Appendix B, Table B2) trended towards decreasing during HD over the
course of both visits (consistent with first project13), while measured extraction efficiency
(see Appendix B, Table B3) did not appear to change during HD over the course of both
visits. These findings help to explain why GFR, which is directly proportional to the product
of F and E, trended towards decreasing over the course of HD.
Szeto el al.14 previously observed an RRF loss rate of -0.083±0.094 mL/min/month
following continuous ambulatory peritoneal dialysis initiation in 645 ESRD patients.
Combining this rate (which has been shown to be identical between HD with high-flux
polysulfone membranes and continuous ambulatory peritoneal dialysis15) with our
patients’ baseline GFR measurements and dialysis vintages yields an average baseline
GFR at dialysis initiation of approximately 11.7 mL/min/1.73m2. This estimate is
consistent with recent trends in Canadian patients’ GFRs at HD initiation. 16

4.4.2 Methodology
In this work, per pixel GFR was computed as the product of the filtration rate
constant and pixel mass, where only cortical pixels were considered. The filtration rate
constant describes the clearance constant of contrast from glomerular capillaries to
Bowman’s capsule in nephrons,17 and the exclusive use of cortical pixels arises from the
fact that glomerular filtration occurs entirely within the cortical segment of the nephron
(i.e., in the renal corpuscle – glomerulus and Bowman’s capsule).18
Previous studies that used imaging techniques to compute GFR have employed
Patlak graphical analysis or various compartment modelling approaches.5,6,17,19 However,
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underlying assumptions behind these methodologies (e.g., negligible contrast transit time
through blood vessels in tissues, negligible efflux of contrast from Bowman’s capsule
back to glomerulus) are likely violated in the case of ESRD/HD renal pathophysiology.9,20
Conversely, the Johnson-Wilson model accounts for transit and potential bidirectional
exchange in the renal corpuscle as contrast flows through the glomerulus.7
Renal structural and functional homogeneity, as well as corticomedullary
differentiation, diminishes as kidney disease progresses.17,21 Therefore, imaging the
entire kidney (compared to a single slice) and augmenting cortical contrast enhancement
(by summing cortical phase images) are necessary for avoiding single-slice extrapolation
bias and improving cortical pixel delineation, respectively, allowing for accurate GFR
measurement.
Our proposed CTP-based GFR measurement approach overcomes important
shortcomings associated with current clinical GFR assessment. GFR measurement could
be confounded by extra-renal clearance, as well as tubular secretion or reabsorption, of
the GFR agent (including contrast) used for the measurement.2 These confounding
effects undermine the utility of commonly used GFR measurement methods, as well as
endogenous and exogenous filtration markers. Standard clinical GFR measurement
methods are based on measuring the blood or urine clearance of GFR agents. Since
blood goes everywhere in the body, the removal mechanisms of these agents could be
glomerular filtration, other extra-renal clearance routes as well as tubular mechanisms. In
addition, while urine collection does ensure that one is measuring what is cleared by the
glomerulus, creatinine and urea are secreted and reabsorbed, respectively, by the
proximal tubule of the nephron, making GFR measurements based on urinary clearance
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of these agents inaccurate. On the other hand, our CT-based method directly measures
the removal of contrast in blood delivered to the afferent arterioles of glomeruli by limiting
the analysis to the cortical region of the kidney, making this technique free of influence of
extra-glomerular sources of clearance, as well as tubular secretion or reabsorption. The
rapid scan time also ensures that F·E can be reliably estimated by the deconvolution
method. Finally, CTP is a favorable imaging modality because it yields additional useful
anatomical and functional information. This modality is also readily available and relatively
inexpensive compared to magnetic resonance and nuclear medicine approaches.

4.4.3 Potential Weaknesses, Limitations and Concerns
We performed three contrast-enhanced scans for this work, but only one (pre-HD)
would be necessary in a clinical setting. Previous work has shown that HD with high-flux
polysulfone membranes clears contrast media22 and that iopamidol in particular is cleared
by HD,23 suggesting that pre-HD CTP-based GFR quantification does not result in
significant contrast agent retention. While contrast media have historically been
discouraged from clinical use in kidney disease patients, recent reports have questioned
the nephrotoxic nature of contrast media, where there has been no conclusive evidence
of contrast-induced nephropathy in HD patients.24
Our approach carries a few additional limitations. Firstly, each GFR measurement
requires a ~8 mSv dose CTP scan. However, CTP-based GFR measurement could be
performed infrequently, limited to decisions regarding HD dosing/scheduling adjustments.
In addition, the time needed for radiation-induced cancer manifestation25 is much greater
than HD patient life expectancy.26 Secondly, we did not validate our findings against any
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other GFR assessments. However, there is in fact no gold standard GFR assessment
technique for ESRD patients on HD.2 Thirdly, renal tissue density was assumed to be
1.050 g/cm3. While this value is for healthy tissue, there is no published ESRD kidney
density data available. Finally, our approach is based on certain technical requirements,
including hardware (CTP-capable scanner with sufficient coverage) and software
requirements (noise reduction and motion correction); even though they are becoming
more widely available.

4.5

Conclusion
The results of this work represent the first imaging-based assessment of GFR in

HD patients. Using CT perfusion imaging, physiologically realistic GFR values were
measured over the course of two HD sessions. These preliminary findings demonstrate
the feasibility of this approach in terms of reliability and accuracy, and provide early
evidence of the clinical potential that CT perfusion imaging has for GFR measurement in
ESRD patients on HD.

4.6
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CHAPTER 5
5

Summary and Future Directions
For the better part of a century, hemodialysis (HD) has been used to treat

individuals with impaired renal function.1 As the medical field progressed and technology
advanced, HD-based renal replacement therapy has been become more effective,
efficient, and safe. However, despite the evolution of this important treatment modality,
end-stage renal disease (ESRD) patients on HD continue to suffer from various
comorbidities, substandard quality of life, and low rates of survival.2 By exploring how HD
impacts different organs and vascular beds, along with the downstream clinical
consequences of these effects, the mechanisms behind the development of HD
complications can be understood and potential therapeutic solutions can be developed.
This philosophy was applied to the research projects of this thesis, where
computed tomography perfusion (CTP) imaging was used to non-invasively assess multiorgan hemodynamics during HD. CT perfusion is a dynamic contrast-enhanced imaging
technique that can provide absolute measurements of various hemodynamic parameters.
All three projects were based on data collected from a single clinical trial, where HD
patients were randomized to receive either standard or cooled HD first in a two-visit,
crossover study design. During each visit, CTP imaging was performed before, during
and after HD without any interruption to the patient’s treatment.
The novel findings of our research studies provide important groundwork regarding
the effects of HD on the kidneys and liver, and the therapeutic potential of dialysate
cooling (DC) for the hemodynamic and functional protection of these organs. In this final
chapter of the thesis, the project objectives will be revisited, important research findings
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will be summarized, clinical impact will be considered, and potential future research
directions will be discussed.

5.1

Summary of Projects: Motivations, Objectives and Findings

5.1.1 Project 1: kidney blood flow and residual renal function loss
The maintenance of even minimal levels of residual renal function (RRF) in ESRD
patients correlates with improved clinical outcomes and survival.3 However, RRF
characteristically declines rapidly upon the initiation of HD,4 with recurrent renal ischemic
insults hypothesized to be responsible.5 This hypothesis was tested in the first project of
this thesis, which had the following objectives:
1. Examine how HD affects renal perfusion
2. Explore the relationship between changes in renal perfusion and myocardial
dysfunction (a hallmark of HD-induced circulatory stress) during HD
3. Investigate whether cooling can protect the kidneys from HD-induced circulatory
stress
Renal perfusion and myocardial injury (i.e., myocardial stunning) were evaluated
using CTP imaging and speckle-tracking echocardiography, respectively. The most
important findings of this project are as follows:
1. Renal perfusion deceased to 81.6% of baseline (P<0.005) during HD and
recovered to 95.1% of baseline after HD
2. There was a correlation between the severity of renal ischemia and the number of
stunned myocardial segments during HD (r=-0.33; P<0.05)
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3. With DC, renal perfusion deceased to 89.2% of baseline during HD and recovered
to 94.3% of baseline after HD
We demonstrated that renal perfusion significantly deceases during HD and that
DC trends towards mitigating this decrease. In addition, renal ischemia correlated with
myocardial injury during HD. Recurring renal ischemic insults over many HD sessions
represents the preliminary pathophysiological characterization of HD-mediated residual
renal function loss in this patient population.

5.1.2 Project 2: liver blood flow and function, and endotoxemia
Endotoxemia correlates with the presence of cardiovascular complications and a
higher mortality risk, and is commonly found in HD patients, who have increased
endotoxin levels compared to healthy people and earlier stage chronic kidney disease
(CKD) patients.6 The liver is normally responsible for clearing endotoxin,7 suggesting that
HD may disrupt liver hemodynamics and function. This idea was explored in the second
project of this thesis, which had the following objectives:
1. Examine how HD affects hepatic perfusion and function
2. Explore the relationship between changes in hepatic perfusion and endotoxin
levels during HD
3. Investigate if cooling can maintain liver hemodynamics and limit systemic exposure
to endotoxin
Hepatic perfusion, hepatic function (i.e., clearance rate of indocyanine green, ICG)
and endotoxin levels were assessed using CTP imaging, pulse-dye densitometry and the
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limulus amoebocyte lysate assay, respectively. The most important findings of this project
are as follows:
1. During HD, portal vein perfusion increased to 111.1% of baseline (P=0.14) and the
ICG clearance rate deceased to 85.5% of baseline (P=0.016)
2. Endotoxin levels increased to 119.6% of baseline during HD (P=0.15) and to
128.4% of baseline after HD (P=0.037)
3. With DC, all of these changes were mitigated: portal vein perfusion changed to
100.8% of baseline during HD, ICG clearance rate changed to 95.2% of baseline
during HD, and endotoxin levels changed to 107.8% and 105.3% of baseline
during and after HD, respectively
We showed that there is concurrent redistribution of hepatic perfusion and
decrease in liver function during HD, and that DC trends towards ameliorating these
changes. Together, these changes help explain the high prevalence of endotoxemia
observed in HD patients.

5.1.3 Project 3: measuring GFR in HD patients using CTP
The current clinical protocol for assessing glomerular filtration rate (GFR) in ESRD
patients on HD is cumbersome, time-consuming and inaccurate,8 causing the adjustment
of a patient’s HD prescription in order to optimize renal replacement therapy to be difficult
to perform and often ignored in the clinical setting.9 However, CTP-based measurement
of GFR has the potential to overcome the limitations of conventional measurement
techniques10 and was the focus of the third project of this thesis, which had the following
objectives:
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1. Develop methodology for CTP-based GFR assessment
2. Explore the feasibility of using CTP imaging to quantify GFR in HD patients
3. Assess how GFR changes over the course of HD
The filtration rate constant and cortical mass of the kidneys were measured by
applying distributed parameter-based tracer kinetic modelling analysis and boosting
corticomedullary differentiation, respectively, to CTP images. The most important findings
of this project are as follows:
1. Baseline measured GFR values were 2.6 and 2.6 mL/min/1.73m2 (left kidney) and
1.7 and 1.5 mL/min/1.73m2 (right kidney) for the first and second visits, respectively
2. Total baseline measured GFR values were 4.3 and 4.0 mL/min/1.73m2 (not
significantly different) for the first and second visits, respectively
3. GFR appeared to fluctuate over the course of HD during both study visits (first visit:
before to during to after HD → 4.3 to 2.2 to 2.4 mL/min/1.73m2, second visit: before
to during to after HD → 4.0 to 2.3 to 3.3 mL/min/1.73m2)
Our novel methodology yielded physiologically realistic GFR values in actual HD
patients. These results, together with the speed, utility and accessibility of CTP imaging,
showcases the clinical feasibility of this approach.

5.2

Clinical impact
The novel methodology and important findings outlined in the research projects of

this thesis have the potential to impact the clinical management of HD patients in a
positive and meaningful way. The hemodynamic and functional measurements we
performed help to identify some of the previously unexplored effects of HD-induced
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circulatory stress on the kidneys and liver, which introduces new avenues for clinical
research and therapeutic intervention.

5.2.1 Heterogeneity of hemodynamic response to HD
One of the most prominent features of our renal and hepatic perfusion data was
the observed heterogeneity in hemodynamic response to HD-induced circulatory stress.
In particular, we found that renal perfusion decreased during HD in approximately two
thirds of patients, with the remaining third having no change, or even an increase, in
kidney blood flow. Similarly, changes in hepatic perfusion (total, hepatic arterial, portal
venous) during HD varied among patients, with about half of patients having increased
blood flow and the other half having decreased blood flow. By studying this heterogeneity
in response (which is characteristic of HD patients11-13) in more patients, we might be able
to predict an individual’s hemodynamic response to HD and develop strategies to mitigate
the potential negative effects.
The primary factors involved in determining how a vascular bed will
hemodynamically react to HD-induced circulatory stress include: (1) the cardiac output
response, (2) the baroreflex sensitivity, and (3) additional organ-specific autoregulatory
mechanisms.11 These factors have been explored and described to varying degrees in
CKD and ESRD, but have not yet been integrated together with perfusion measurements
to fully describe the heterogeneous response of patients to HD. In particular, (1) cardiac
output has been shown to decrease during HD,14,15 (2) patients with compromised
baroreflex sensitivity have been found to be more vulnerable to ultrafiltration,11 and (3)
the

kidney’s

hemodynamic

regulation
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mechanisms

(e.g.,

myogenic

reflex,

tubuloglomerular feedback, renin-angiotensin system) become impaired in kidney
disease.16-18 The relationship between kidney disease and/or HD, and the liver’s
hemodynamic regulation (e.g., hepatic arterial buffer response, hepatorenal reflex19,20), is
unknown.
We conducted a preliminary analysis of the relationship between changes in
cardiac output, blood pressure, and renal/hepatic perfusion in our patients. Based on the
Stewart-Hamilton equation, cardiac output was determined from CTP21-23 as follows:
𝐶𝑎𝑟𝑑𝑖𝑎𝑐 𝑂𝑢𝑡𝑝𝑢𝑡 =

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑
𝑎𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛– 𝑣𝑠– 𝑡𝑖𝑚𝑒 𝑐𝑢𝑟𝑣𝑒

There were a few key findings of this analysis:
•

During HD, there were significant drops in cardiac output (P=0.01) and blood
pressure (P=0.001), coinciding with the results of previous studies14,24

•

During HD, changes in cardiac output correlated with changes in renal perfusion
(r=0.38, P=0.004) and hepatic perfusion (r=0.66, P=0.007)

•

Approximately half of patients demonstrated a drop in both cardiac output and
blood pressure during HD, but these patients did not necessarily have a
corresponding decrease in organ perfusion, suggestive of organ-specific
autoregulatory activity
o Project 1: 14/29 patients (48%) demonstrated a drop in both cardiac output
and blood pressure during HD → of these, 11/14 (79%) patients
demonstrated a drop in renal perfusion
o Project 2: 8/15 patients (53%) demonstrated a drop in both cardiac output
and blood pressure during HD → of these, 4/8 (50%) patients demonstrated
a drop in hepatic perfusion
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These interesting results help to emphasize the importance of studying the hemodynamic
response to HD-induced circulatory stress, as well as the role of CTP in measuring multiorgan perfusion and cardiac output (i.e., possible to assess renal perfusion, hepatic
perfusion and cardiac output from a single CTP scan).

5.2.2 CTP for hemodynamic and functional measurements in HD patients
Patients with ESRD typically receive their HD treatments in a clinical setting (rather
than at home). Therefore, the ideal modality for acquiring intradialytic hemodynamic
measurements is one that is minimally invasive, does not disrupt HD treatment, and can
be performed rapidly. These criteria are satisfied by CTP, an imaging modality that is
readily available, relatively inexpensive, and that can perform multi-organ physiologic
measurements in approximately two minutes without disrupting HD. While magnetic
resonance imaging and positron emission tomography can be used to perform
intradialytic perfusion measurements,14,25-27 these

modalities are

hindered

by

contraindications (metal, pacemaker, etc.), availability, and scan time concerns, limiting
their use for this application. The research projects of this thesis were the first to ever use
CTP for acquiring hemodynamic measurements during HD. Despite its advantages, CTP
imaging has a couple of drawbacks: it requires the administration of exogenous contrast
media, and it exposes the patient to ionizing radiation. However, the severity of these
drawbacks has been ameliorated with time, thanks to innovations in technology,
improvements in methodology, changes in clinical practice, and conducting of higherquality clinical trials.
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The main sources of evidence for contrast-induced nephropathy (CIN) are based
on studies with some combination of the following aspects:28
•

Use of “unsafe” contrast media (i.e., ionic, high-osmolarity, etc.)

•

Contrast was administered intraarterially for invasive angiocardiographic
procedures

•

No control groups where contrast material was not administered

•

Not designed to directly assess the relationship between intravenous contrast
media administration and CIN

To date, no large-scale randomized control trials have been conducted to more
definitively conclude whether modern contrast-enhanced imaging protocols (e.g., CTP)
cause CIN, particularly in patients with GFR <30 mL/min/1.73m2.29 However, over the
past decade or so, a number of reviews, observational studies controlling for known
confounders, meta-analyses, and retrospective studies utilizing propensity-matched
analysis have consistently found that the incidence of diminished renal function does not
significantly differ between patients receiving contrast-enhanced versus non-contrast
imaging scans.28,29 While more work is required to accurately and confidently characterize
the relationship between contrast administration and changes in renal function, the clinical
utility of CTP (and other modern contrast-enhanced imaging techniques), together with
the current level of scientific evidence, supports the use of this modality for performing
the important intradialytic hemodynamic and functional measurements presented in the
research projects of this thesis.
Patients involved in our studies received a radiation dose of approximately 8 mSv
during every CTP scan. This dose is equivalent to about ten abdominal radiographs and
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is approximately three times greater than the local natural annual background dose (~3
mSv).30 While this dose is nontrivial, it is important to note that, as previously mentioned
in chapter 4, it typically takes decades for radiation-induced cancer to manifest.31 Patients
with ESRD receiving maintenance HD have an average age of >60 years and a life
expectancy of under five years.32 Considering these time frames, the lifespan of HD
patients exposed to radiation from medical imaging is likely not be affected in any
significant way. In addition, CT dose-reduction techniques and technologies have been
the focus of many research initiatives, with various approaches finding their way into the
clinical workflow. For example, automatic exposure control (modulation of tube current
based on regional x-ray attenuation) and iterative reconstruction, together with gradual
improvements in filter and detector designs and technologies, are all current
advancements in CT dose-reduction that are currently being implemented.33,34 Novel
approaches that are being researched, such as compressed sensing (reconstruction of
reduced-projection image data) and machine learning techniques (e.g., deep learning for
reconstruction and/or denoising of low-dose image data), represent exciting prospects in
dose-reduction technology.35,36

5.2.3 Effectiveness of DC
In all the research projects of this thesis, DC was applied as a therapeutic
intervention to ameliorate HD-induced circulatory stress. We implemented a fixedtemperature cooling approach, whereby the dialysate was cooled to 35°C for all patients,
regardless of baseline body temperature or body temperature fluctuations during HD. It
was consistently found that with DC, changes in perfusion and function did not differ
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significantly from changes seen during standard HD. Although this prevented us from
concluding that DC was an effective intradialytic intervention in these studies, we did
observe that cooling did not cause harm in terms of worsening the severity of changes in
perfusion and function during HD, and even trended towards positively affecting these
metrics.
Two plausible reasons for the ineffectiveness of DC in our studies are (a) that we
used a fixed-temperature cooling approach, and (b) that there was only a single session
of cooled HD.
Several forms of DC have been explored in research studies, with the most
prevalent types being fixed-temperature cooling (as in our studies), baseline-temperature
cooling (based on pre-HD body temperature), and feedback-temperature cooling (based
on continual monitoring of body temperature during HD to adjust DC level).37-39 While
being the easiest to implement, fixed-temperature cooling ignores the relatively wide
range of baseline body temperatures among individuals.40 As a result, DC could range
from <0.5°C to >2°C depending on the individual, helping to explain why its effectiveness
and tolerability was not universal in our studies. On the other hand, trials implementing
baseline-temperature cooling or feedback-temperature cooling have observed a greater
effectiveness of DC, demonstrating the importance of an individualized approach to DC.4143

While it is possible to implement baseline-temperature cooling universally, feedback-

temperature cooling requires additional resources (e.g., biofeedback temperature
monitoring device) that limits its clinical uptake.37,38
Most research studies exploring DC were similar to ours in terms of design, where
patients were randomized to receive a single or a few sessions of standard or cooled HD
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first before being crossed over to the other arm of the study.37,38 While this sort of design
is appropriate for evaluating acute HD-induced hemodynamic and functional changes
(e.g., IDH, renal and hepatic perfusion, myocardial stunning, etc.), it does not enable the
study of long-term consequences of DC on downstream clinical outcomes. For instance,
although we observed only trends toward improvements in renal and hepatic perfusion
and function with DC during a single HD session, it may be that if this intervention was
implemented consistently over the course of several months/years that significant clinical
outcomes (e.g., smaller decline in RRF, lower levels of endotoxemia, etc.) could be seen.
Because of the different types of cooling approaches, various metrics for
determining cooling efficacy, and limited longitudinal study of cooling effectiveness, the
clinical potential of DC has been questioned and its clinical uptake has been slow.
However, there is currently a large-scale, multi-center randomized control trial being
conducted (MyTEMP trial44) that aims to definitively demonstrate the effectiveness of
baseline-temperature DC by reporting major cardiovascular outcomes over the course of
several years.

5.3

Next Steps
Moving forward, there are several important and exciting next steps related to the

research work of this thesis. Our work has demonstrated that CTP is a favorable imaging
modality for use during HD: scan time is very short, axial coverage is generous (i.e., can
image multiple structures in a single scan), and there is no interruption to HD treatment.
Therefore, CTP can be used for assessing the effects of HD-induced circulatory stress
on other organs and vascular beds, as well as evaluating the efficacy of other therapeutic

141

interventions. As alluded to in previous sections, it may be worthwhile to explore other
types of DC, other intradialytic therapeutic interventions entirely, or even combining
multiple interventions, for ameliorating HD-induced circulatory stress and maintaining
renal and hepatic perfusion and function during HD.
The first and second projects of this thesis were performed with a relatively small
number of participants and assessed intradialytic changes in renal and hepatic perfusion
and function over the course of just a single standard HD session. It would be interesting
to perform longitudinal studies with more participants where metrics of interest (e.g.,
intradialytic change in renal and hepatic perfusion) are correlated with the corresponding
clinical outcomes of relevance over a longer time period (e.g., changes in RRF and
endotoxemia levels after one year). These kinds of analyses would give greater context
to, and increase the clinical value of, the perfusion and function measurements performed
in this thesis.
Next, while no true gold standard GFR measurement approach exists for ESRD
patients on HD, some sort of validation study is necessary to strengthen the findings of
the third project. As the best metrics to evaluate the clinical utility of a technique are
clinical outcomes and survival, it may be worthwhile to perform a study where these
metrics (in addition to, for instance, residual urine output volume) are correlated to HD
patient GFR values measured using both our CTP-based technique, as well as measured
using inulin clearance with timed urine collection. If our CTP-based approach yields the
better results, then it has the potential to become the new gold standard GFR
measurement technique in HD patients.
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Finally, we have begun working on a collaborative, multidisciplinary project that is
focused on designing and running virtual HD sessions. Using CTP data from HD patients,
we are able to generate 3D reconstructions of multi-organ perfusion (Figure 5.1) for fractal
dimension texture analysis and heterogeneity quantification. Then, by combining the
reconstruction data together with various biophysical inputs (e.g., mathematically
optimized spatial blood flow distribution, organ shape, blood vessel morphometry,
autoregulation mechanisms, etc.), a mathematical model of the patient-specific response
to HD-induced circulatory stress can be generated. From here, it would be possible to
simulate and run in silico sessions of HD while having full control over the various
adjustable technical and clinical parameters. This will allow us to predict the patientspecific response to HD, as well as to optimize treatment parameters accordingly, prior
to exposing ESRD patients to the circulatory stress of HD.

Figure 5.1 CTP-based 3D reconstructions of multi-organ perfusion. Reconstructions of the liver and kidneys
are shown. Image courtesy of Dr. Sanjay Kharche.
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Appendices
Appendix A: Supplementary Results for Chapter 3
In addition to liver excretory function, hepatic injury due to HD-induced circulatory
stress was also assessed by measuring liver enzyme levels before and after standard
and cooled HD. A summary of the relative changes in enzyme levels from baseline is
presented in Table A1.

Table A1: Changes in liver enzyme levels with respect to baseline following standard and
cooled HD. The measured enzymes included aspartate transaminase, alanine
transaminase, alkaline phosphatase, and gamma glutamyl transpeptidase, and were
used as measures of liver injury resulting from HD-induced circulatory stress.
% Change Relative to Baseline
Liver Enzyme
After Standard HD

After Cooled HD

Aspartate Transaminase

+19.7

+16.1

Alanine Transaminase

+10.0

+11.3

Alkaline Phosphatase

+11.8

+7.5

Gamma Glutamyl Transpeptidase

+16.7

+11.8
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Appendix B: Supplementary Results for Chapter 4
The GFR was measured in 6 patients whose kidneys were completely captured
with CT perfusion scanning. Summaries of computed GFR values, renal cortical perfusion
values, and renal cortical extraction efficiency values for these patients are given in
Tables B1, B2, and B3, respectively.

Table B1: Calculated GFR based on CT perfusion imaging measurements. Results are
organized according to visit (visit 1 or visit 2, top half of table) and HD type (standard HD
or cooled HD, bottom half of table), where imaging was performed before, during and
after HD. GFR was computed for left (L) and right (R) kidneys separately, then summed
together for total (T) GFR. Shading represents HD sessions where dialysate cooling was
applied.

Pt
#
1
2
3
4
5
6

Before HD
L R T

GFR (mL/min/1.73m2) – Organized by Visit
Visit 1
Visit 2
During HD
After HD
Before HD During HD
L R T L R T L R T L R T

After HD
L R T

6.6

1.6

8.2

4.0

0.6

4.6

3.2

0.4

3.6

7.7

1.1

8.8

3.5

0.9

4.4

3.7

1.3

5.0

1.0

0.6

1.6

0.5

0.3

0.7

1.0

0.6

1.7

1.1

0.5

1.6

0.2

0.2

0.5

0.9

0.7

1.6

1.0

1.7

2.7

0.7

1.3

2.1

0.7

1.2

1.9

0.8

1.8

2.6

1.0

2.1

3.0

1.7

2.6

4.3

0.7

0.4

1.0

0.0

0.3

0.4

0.3

0.3

0.6

0.2

0.1

0.3

0.4

0.2

0.6

0.5

0.4

0.9

3.2

3.4

6.5

2.0

1.9

3.9

2.2

2.0

4.2

3.5

3.0

6.5

1.8

1.9

3.7

2.7

2.6

5.3

3.0

2.5

5.5

0.7

0.8

1.5

1.3

1.3

2.6

2.1

2.3

4.4

0.8

0.8

1.6

1.4

1.0

2.4

GFR
– Organized by HD Type
Standard HD
Cooled HD
Before HD During HD
After HD
Before HD During HD
L R T L R T L R T L R T L R T

After HD
L R T

6.6

1.6

8.2

4.0

0.6

4.6

3.2

0.4

3.6

7.7

1.1

8.8

3.5

0.9

4.4

3.7

1.3

5.0

1.0

0.6

1.6

0.5

0.3

0.7

1.0

0.6

1.7

1.1

0.5

1.6

0.2

0.2

0.5

0.9

0.7

1.6

1.0

1.7

2.7

0.7

1.3

2.1

0.7

1.2

1.9

0.8

1.8

2.6

1.0

2.1

3.0

1.7

2.6

4.3

0.7

0.4

1.0

0.0

0.3

0.4

0.3

0.3

0.6

0.2

0.1

0.3

0.4

0.2

0.6

0.5

0.4

0.9

3.5

3.0

6.5

1.8

1.9

3.7

2.7

2.6

5.3

3.2

3.4

6.5

2.0

1.9

3.9

2.2

2.0

4.2

3.0

2.5

5.5

0.7

0.8

1.5

1.3

1.3

2.6

2.1

2.3

4.4

0.8

0.8

1.6

1.4

1.0

2.4

(mL/min/1.73m2)

Pt
#
1
2
3
4
5
6
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Table B2: Measured renal cortical perfusion based on CT perfusion imaging. Values are
organized according to visit (visit 1 or visit 2, top half of table) and HD type (standard HD
or cooled HD, bottom half of table), where imaging was performed before, during and
after HD. Cortical perfusion was measured for left (L) and right (R) kidneys separately.
Shading represents HD sessions where dialysate cooling was applied.

Pt
#
1
2
3
4
5
6
Pt
#
1
2
3
4
5
6

Renal Cortical Perfusion (mL/min/100g) – Organized by Visit
Visit 1
Visit 2
Before HD During HD
After HD
Before HD During HD
After HD
L
R
L
R
L
R
L
R
L
R
L
R
121.6

36.9

79.6

24.1

59.6

15.9

154.1

28.2

22.6

22.4

21.0

17.6

34.1

20.7

24.5

22.9

22.1

31.7

18.4

26.4

32.0

29.6

34.9

38.8

25.2

11.6

27.0

11.0

14.8

12.0

8.8

7.6

24.2

26.3

24.8

24.9

24.7

32.3

32.4

30.3

15.3

12.7

7.9

5.6

13.5

11.2

17.3

16.3

98.9

30.0

97.6

41.7

9.2

9.2

27.9

25.6

27.0

45.4

57.3

102.5

19.0

6.8

14.9

10.7

27.9

31.7

36.4

32.1

12.6

7.6

11.6

9.8

Renal Cortical Perfusion (mL/min/100g) – Organized by HD Type
Standard HD
Cooled HD
Before HD During HD
After HD
Before HD During HD
After HD
L
R
L
R
L
R
L
R
L
R
L
R
121.6

36.9

79.6

24.1

59.6

15.9

154.1

28.2

22.6

22.4

21.0

17.6

34.1

20.7

24.5

22.9

22.1

31.7

18.4

26.4

32.0

29.6

34.9

38.8

25.2

11.6

27.0

11.0

14.8

12.0

8.8

7.6

32.4

30.3

27.9

31.7

36.4

32.1

24.2

26.3

15.3

12.7

7.9

5.6

13.5

11.2

17.3

16.3
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98.9

30.0

97.6

41.7

9.2

9.2

27.9

25.6

27.0

45.4

57.3

102.5

19.0

6.8

14.9

10.7

24.8

24.9

24.7

32.3

12.6

7.6

11.6

9.8

Table B3: Measured renal cortical extraction efficiency based on CT perfusion imaging.
Values are organized according to visit (visit 1 or visit 2, top half of table) and HD type
(standard HD or cooled HD, bottom half of table), where imaging was performed before,
during and after HD. Cortical extraction efficiency was measured for left (L) and right (R)
kidneys separately. Shading represents HD sessions where dialysate cooling was
applied.

Pt
#
1
2
3
4
5
6
Pt
#
1
2
3
4
5
6

Renal Cortical Extraction Efficiency – Organized by Visit
Visit 1
Visit 2
Before HD During HD
After HD
Before HD During HD
L
R
L
R
L
R
L
R
L
R

After HD
L
R

0.4591

0.6155

0.5589

0.4875

0.6711

0.5371

0.4030

0.6439

0.5187

0.7694

0.5151

0.6214

0.7055

0.7204

0.5762

0.5022

0.6261

0.9079

0.7617

0.6716

0.6736

0.7177

0.7414

0.7407

0.5148

0.5338

0.6191

0.6722

0.4160

0.6027

0.4364

0.4854

0.7017

0.6231

0.4900

0.3379

0.4115

0.6803

0.3755

0.8949

0.5919

0.6781

0.4380

0.5513

0.3354

0.6582

0.6135

0.6835

0.7356

0.7374

0.5642

0.6478

0.7121

0.5100

0.6539

0.6803

0.5337

0.5597

0.5620

0.6487

0.7259

0.6809

0.5754

0.7001

0.6689

0.5985

0.7230

0.7001

0.4165

0.5635

0.6624

0.6001

Renal Cortical Extraction Efficiency – Organized by HD Type
Standard HD
Cooled HD
Before HD During HD
After HD
Before HD During HD
After HD
L
R
L
R
L
R
L
R
L
R
L
R
0.4591

0.6155

0.5589

0.4875

0.6711

0.5371

0.4030

0.6439

0.5187

0.7694

0.5151

0.6214

0.7055

0.7204

0.5762

0.5022

0.6261

0.9079

0.7617

0.6716

0.6736

0.7177

0.7414

0.7407

0.5148

0.5338

0.6191

0.6722

0.4160

0.6027

0.4364

0.4854

0.7017

0.6231

0.4900

0.3379

0.4115

0.6803

0.3755

0.8949

0.5919

0.6781

0.4380

0.5513

0.3354

0.6582

0.6135

0.6835

0.6539

0.6803

0.5337

0.5597

0.5620

0.6487

0.7356

0.7374

0.5642

0.6478

0.7121

0.5100

0.7259

0.6809

0.5754

0.7001

0.6689

0.5985

0.7230

0.7001

0.4165

0.5635

0.6624

0.6001
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Master of Clinical Medical Biophysics, June 2018

Sep 2015 – Jul 2020

Carleton University, Ottawa, Canada
MSc, Medical Physics

Sep 2013 – Aug 2015

York University, Toronto, Canada
BSc with Honors, Biophysics (First Class distinction)

Sep 2009 – Apr 2013

RELEVANT SKILLS & EXPERIENCE
• Skilled in programming and coding with MATLAB, Python, C++, Mathematica, LabVIEW, Java
• Experienced with machining, working with phantoms, electronics and circuits
• Proficient in image processing and analysis, including segmentation (manual and machine learningbased), registration, reconstruction, and texture/heterogeneity quantification
• Experienced in multi-modality functional imaging, including CT and perfusion imaging, optical
imaging and pulsed oximetry, ultrasound and echocardiography, confocal microscopy
• Strong understanding of dual energy and cone-beam CT, PET and SPECT, various MRI techniques
• Experienced with small beam dosimetry and various dosimeters (MOSFET, radiochromic film, TLD)
• Proficient with using electromagnetic, x-ray and optical techniques for target position/motion tracking
• Experience with beam delivery adaptation based on real-time in-room imaging during radiotherapy
• Skilled in linac quality assurance, specializing in Varian (iX and TrueBeam) and CyberKnife
machines
• Proficient in designing, reviewing, and optimizing radiotherapy treatment plans on different
platforms, including the Pinnacle system and CyberKnife’s MultiPlan system
RESEARCH EXPERIENCE
PhD Thesis, Robarts Research Institute, London, Canada
Sep 2015 – Jul 2020
Assessing multi-organ hemodynamic changes during hemodialysis using CT perfusion imaging
• Used perfusion imaging and tracer kinetic modeling to quantify and describe how hemodialysis
affects organ-specific blood flow and function in end-stage renal disease
• Demonstrated significant reduction in renal perfusion during hemodialysis, which is a potential key
pathophysiological factor leading to residual renal function decline in end-stage renal disease patients
• Developed a semi-automated algorithm to import, adjust, segment and perform quantitative analysis
on CT images and multi-parametric functional maps
MSc Thesis, The Ottawa Hospital Cancer Center, Ottawa, Canada
Sep 2013 – Aug 2015
Evaluating the 4D RADPOS dosimetry system for dose and position QA of CyberKnife radiotherapy
• Performed end-to-end Monte Carlo-based treatment planning for CyberKnife and gained proficiency
in small beam dosimetry and SBRT plan optimization
• Conducted dosimetric and positional evaluations of CyberKnife using custom phantom types and
configurations under various beam delivery regimes, demonstrating with RADPOS that CyberKnife’s
motion tracking system struggles to compensate for irregular patient motion patterns
• Developed a semi-automated algorithm to import CyberKnife and RADPOS position data, transform
the data into a common coordinate system, and perform numerical and graphical analysis
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Research Assistant, Kidney Clinical Research Unit, London, Canada
Sep 2017 – Jul 2020
Exploring patient-specific response to dialysis using mathematical models of organ perfusion
• Assisted with performing 3D reconstructions of multi-organ blood flow using CT perfusion images
for fractal dimension texture analysis and heterogeneity quantification
• Helped generate patient-specific models of perfusion based on mathematically optimized spatial
blood flow distribution, organ shape, blood vessel morphometry, and autoregulation mechanisms
Research Assistant, York University, Toronto, Canada
May 2013 – Aug 2013
Assessing novel detector designs for high-energy particle physics applications with in silico models
• Performed computer simulations of particle beams incident on a detector as an application for CERN
CVD diamond anti-proton beam detectors
• Developed a parallel computing-based program in Mathematica and LabVIEW to determine particle
beam parameters and coordinates based on intensity values from simulated detector
NSERC-USRA Research Assistant, York University, Toronto, Canada
May 2011 – Sep 2011
Construction and characterization of interference filter-stabilized diode lasers
• Assisted with construction of home-made, interference filter-stabilized diode lasers for use in
industry-standard commercial gravimeters and cold atom experiments
• Designed custom circuits and mechanical parts for laser system augmentation, and performed laser
system characterization in terms of line width and mode structure
RAY (Research At York) Research Assistant, York University, Toronto, Canada Jan 2011 – Apr 2011
Fluorescence measurements of mitochondrial and chloroplast activity in Eremosphaera viridis
• Examined the use of Rhodamine 123 and chlorophyll autofluorescence to monitor the physiological
action of mitochondrial respiration and chloroplast photosynthetic activity in algae cells
• Performed 3D reconstructions of mitochondrial and chloroplast spatial locations using confocal
microscopy and quantified fluorescence intensity to characterize mitochondrial-chloroplast
interactions
PUBLICATIONS, PRESENTATIONS & ABSTRACTS
Peer-Reviewed Publications and Abstracts
• Marants R, Qirjazi E, Grant CJ, Lee TY, McIntyre CW. Renal Perfusion during Hemodialysis:
Intradialytic Blood Flow Decline and Effects of Dialysate Cooling. J Am Soc Nephrol. 2019;30:10861095 (publication)
• Marants R, Vandervoort E, Cygler JE. Evaluation of the 4D RADPOS Dosimetry System for Dose
and Position Quality Assurance of CyberKnife. Med Phys. 2018;45:4030-4044 (publication)
• Filler G, Ramsaroop A, Stein R, Grant CJ, Marants R, So A, McIntyre CW. Is Testosterone
Detrimental to Renal Function? Kidney Int Rep. 2016;1:306-310 (publication)
• Marants R, Vandervoort E, Cygler JE. Quality Assurance Using the RADPOS System for 4D
Radiotherapy with CyberKnife. Med Phys. 2015;42:3485-3485 (poster presentation, AAPM 2015)
• Marants R, Vandervoort E, Cygler JE. Dose and Position Quality Assurance Using the RADPOS
System for 4D Radiotherapy with CyberKnife. IFMBE Proceedings. 2015;51:599-602 (oral
presentation, IUPESM World Congress 2015)
• Marants R, Vandervoort E, Cygler JE. Dose and Position Quality Assurance Using the 4D RADPOS
System for CyberKnife Radiotherapy. Med Phys. 2014;41:11-11 (poster presentation, COMP 2014)
Publications in Preparation
• Marants R, Qirjazi E, Lee TY, McIntyre CW. Exploring the Link Between Hepatic Perfusion and
Systemic Endotoxemia in Hemodialysis Patients
• Marants R, McIntyre CW, Lee TY. Feasibility of Measuring Glomerular Filtration Rate in End-Stage
Renal Disease Patients using CT Perfusion Imaging
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National and International Conferences
• Marants R, Qirjazi E, Grant CJ, Lee TY, McIntyre CW. Using CT Perfusion Imaging to Measure
Kidney Blood Flow during Hemodialysis in End-Stage Kidney Disease Patients (oral presentation,
AAPM 2019)
• Marants R, Qirjazi E, Grant CJ, Lee TY, McIntyre CW. Residual Renal Function Loss in
Hemodialysis Patients: Is Kidney Stunning the Culprit & Can Dialysate Cooling Help? (poster
presentation, ASN 2018)
• Qirjazi E, Marants R, Mio MA, Urquhart B, Lee TY, McIntyre CW. Hepatic Response to Cooler
Hemodialysis (poster presentation, ASN 2018)
• Kharche SR, Marants R, Qirjazi E, Kassay AD, Joseph J, McDougall KD, Lee TY, McIntyre CW.
Understanding the Effects of Hemodialysis on Blood Flow: An Imaging-Mathematical Modeling
Study (poster presentation, ASN 2018)
• Marants R, Grant CJ, Qirjazi E, McIntyre CW, Lee TY. Renal CT Perfusion Imaging during
Hemodialysis: Relating Kidney Blood Flow to Residual Renal Function Loss (oral presentation,
CARO-COMP-CAMRT 2018)
• Marants R, Qirjazi E, McIntyre CW, Lee TY. Dialysate Cooling during Hemodialysis: Assessment of
Liver Hemodynamics using CT Perfusion Imaging (oral presentation and science highlight, AAPM
2018)
• Marants R, Grant CJ, McIntyre CW, Lee TY. CT Perfusion Imaging of the Liver during
Hemodialysis: Assessment of Hepatic Blood Flow Distribution (oral presentation, COMP 2017)
• Marants R, Grant CJ, Lee TY, McIntyre CW. Renal Perfusion Falls during Hemodialysis: An
Explanation for the Loss of Residual Renal Function in Dialysis Patients (poster presentation, ASN
2016)
• Grant CJ, Marants R, Tonial N, Velenosi T, Urquhart B, Lee TY, McIntyre CW. Hepatic Response to
Hemodialysis: Consequences for Uremic Toxin Exposures and Multi-Organ Injury (poster
presentation, ASN 2016)
• Mok C, Winter S, Beica H, Barrett B, Berthiaume R, Vorozcovs A, Yachoua F, Afkhami-Jeddi N,
Marants R, Aggarwal M, Kumarakrishnan A. Atom Trapping Laboratory for Upper Level
Undergraduate Students (poster presentation, APS DAMOP 2012)
• Afkhami-Jeddi N, Marants R, Berthiaume R, Kumarakrishnan A. Analysis of Stability of Homebuilt
Diode Lasers for Precise Measurements of Gravitational Acceleration (oral presentation, CUPC 2011)
Local and Regional Conferences
• Marants R, Qirjazi E, McIntyre CW, Lee TY. Exploring the Effects of Standard and Cooled
Hemodialysis on Liver Hemodynamics and Systemic Endotoxemia using CT Perfusion Imaging (oral
presentation, London Imaging Discovery 2019)
• Marants R, Qirjazi E, McIntyre CW, Lee TY. Exploring the Link Between Liver Blood Flow and
Systemic Endotoxemia during Hemodialysis: A CT Perfusion Study (poster presentation, Robarts
Retreat 2019)
• Marants R, Qirjazi E, Grant CJ, McIntyre CW, Lee TY. Exploring the Effects of Standard and Cooled
Hemodialysis on Renal Blood Flow using CT Perfusion (oral presentation, ImNO and LHRD 2019)
• Marants R, Qirjazi E, McIntyre CW, Lee TY. Evaluating the Effects of Dialysate Cooling on Liver
Hemodynamics during Hemodialysis: A CT Perfusion Study (poster presentation, Robarts Retreat
2018)
• Marants R, Qirjazi E, McIntyre CW, Lee TY. How does Dialysate Cooling during Hemodialysis
affect Kidney Blood Flow and Residual Renal Function? A CT Perfusion Study (electronic poster
presentation, London Imaging Discovery 2018)
• Marants R, Qirjazi E, McIntyre CW, Lee TY. Exploring the Effects of Dialysate Cooling on Liver
Hemodynamics during Hemodialysis with CT Perfusion (poster presentations, ImNO and LHRD
2018)
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Marants R, Grant CJ, McIntyre CW, Lee TY. CT Perfusion Imaging of the Liver during
Hemodialysis: Assessment of Changes in Liver Perfusion Distribution and Hepatic Function (poster
presentation, Robarts Retreat 2017)
Marants R, Grant CJ, Jiang N, Huang IL, Wang Q, Lee TY, McIntyre CW. Renal Perfusion Falls
during Hemodialysis: An Explanation for the Loss of Residual Renal Function in Dialysis Patients
(poster presentations, ImNO and LHRD 2017)
Marants R, Grant CJ, Stewart EE, Hadway J, McIntyre CW, Lee TY. CT Perfusion Imaging for
Evaluating the Effects of Dialysis on Liver Perfusion (oral presentation, London Imaging Discovery
2016)
Marants R, Grant CJ, Stewart EE, Hadway J, McIntyre CW, Lee TY. Evaluating the Effects of
Dialysis on Liver Perfusion using CT Perfusion Imaging (poster presentations, ImNO and LHRD
2016)

Other Publications (not peer-reviewed)
• Winter S, Beica H, Mok C, Barrett B, Berthiaume R, Vorozcovs A, Yachoua F, Afkhami-Jeddi N,
Marants R, Aggarwal M, Kumarakrishnan A. Resource Letter for Advanced Laboratory Courses on
Laser Spectroscopy and Atom Trapping. 2013.
• Marants R, Lew RR. Viridae Flourescence: Fluorescence intensity measurements of mitochondrial
and chloroplast activity in Eremosphaera viridis. 2011.
AWARDS & SCHOLARSHIPS
CAMPEP QA-Ship
Western University, London, Canada
2017 – 2019, $3000/year

Certificate of merit poster award
London Imaging Discovery Day
London, Canada, Jun 2018
Honorable mention poster award
Imaging Network Ontario Symposium
Toronto, Canada, Mar 2018
Cum Laude abstract award
Imaging Network Ontario Symposium
Toronto, Canada, Mar 2016

Schulich Graduate Scholarship & Western
Graduate Research Scholarship
Western University, London, Canada
2015 – 2020, $8800/year
COMP Student Council Travel Award &
Graduate Student Travel/Research Award
Carleton University, Ottawa, Canada
2014, $1000
Carleton University Department Scholarship
Carleton University, Ottawa, Canada
2013 – 2014, $3000/year
NSERC Undergraduate Student Research Award
York University, Toronto, Canada
2011, $6000
YorkU Renewable Entrance Scholarship &
Science and Engineering Entrance Scholarship
York University, Toronto, Canada
2009 – 2010, $3000/year

WORK & TEACHING EXPERIENCE
Radiotherapy Quality Assurance London Regional Cancer Program, London, Canada
2017 – 2019
• Independently performed weekly, biweekly and monthly quality assurance tests (mechanical and
machine output) for two Varian radiotherapy linear accelerators (iX and TrueBeam)
• Provided detailed quality assurance reports to medical physicists and radiation therapists
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Teaching Assistant Carleton University, Ottawa, Canada
2013 – 2015
• Lead students through tutorials and laboratory experiments, offering support and promoting critical
thinking and application of classroom and textbook concepts
• Performed grading of laboratory reports and tutorial tests, as well as proctoring during tests and
exams
VOLUNTEER EXPERIENCE
Discovery Days in Health Sciences St. Joseph’s Health Care, London, Canada
• Presented and promoted medical science research to visiting high school students
• Discussed post-secondary education options and pathways with students

2017 and 2018

Let’s Talk Science York University & Carleton University, Toronto and Ottawa, Canada 2012 and 2015
• Promoted the study of science to elementary school students by introducing them to basic scientific
principles and leading them through engaging hands-on demonstrations and experiments
• Demonstrated and explained various experimental aspects of an undergraduate biophysics laboratory
to visiting high school students
Emergency Ward Mackenzie Richmond Hill Hospital, Richmond Hill, Canada
• Assisted with medical procedures such as suturing and casting
• Prepared clean patient beds and sorted medical charts

2012 – 2013

Undergraduate Biophysics Laboratory York University, Toronto, Canada
• Performed and evaluated various biophysics laboratory experimental setups and procedures
• Installation, configuration and repair of experiment-specific equipment

2010

LANGUAGES
• Native proficiency in English
• Professional working proficiency in Russian
• Limited working proficiency in French and Hebrew
EXTRACURRICULAR ACTIVITIES
Intramural Sports Western University, London, Canada
• Helped put together teams and organize practices for a variety of co-ed team sports

2017 – 2019

Medical Biophysics CAMPEP Club Chair Western University, London, Canada
2017 – 2018
• Organized club meetings for CAMPEP students to discuss medical physics news and conferences,
work on CCPM problem sets, and listen to presentations by guest speakers
• Communicated with and arranged for guest speakers (including medical physics residents, clinical
medical physicists, Western alumni) to present at club meetings
Biophysics Club Member York University, Toronto, Canada
2010 – 2013
• Promoted biophysics program to prospective students and biophysics courses to current students
• Assisted with organizing club meetings and events, such as guest lectures and demonstrations
Ballroom Dance Club Instructor York University, Toronto, Canada
• Planned classes and taught basic ballroom dancing choreography and techniques
• Helped organize special events and social outings for club members

2010

Competitive Ballroom Dancing Dance Mania & Dance Life Studios, Toronto, Canada
1999 – 2013
• Performed at city-wide recitals and shows, and competed in local, national and international
competitions
• 2012 Ontario Pre-Champ Ballroom and Latin champion and Champ Ballroom and Latin top 8 finalist
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